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Summary	
Polo-like	kinase	1	(Plk1)	is	a	serine-threonine	protein	kinase	widely	accepted	as	one	
of	 the	 master	 regulators	 of	 cell	 cycle.	 Overexpression	 of	 Plk1	 is	 a	 frequent	
occurrence	 in	an	array	of	different	human	 tumor	 types	and	 it	 is	usually	 correlated	
with	poor	prognosis	in	patients.	However,	very	little	is	known	about	the	exact	role	of	
Plk1	in	tumorigenesis.	Here,	we	use	inducible	mouse	models	to	determine	the	in	vivo	
consequences	of	Plk1	overexpression.	During	this	study,	we	established	that	Plk1	is	
not	an	oncogene	and	overexpression	of	Plk1	has	a	strong	tumor	suppressive	effect	
on	Her2	or	Kras	driven	breast	cancer.	Furthermore,	 tumors	with	elevated	 levels	of	
Plk1	displayed	evidence	of	whole	genome	doubling	coupled	with	increased	levels	of	
aneuploidy.	Histological	characterization	of	murine	mammary	glands	prior	to	tumor	
development	 affirmed	 a	 correlation	 between	 Plk1	 overexpression	 and	 increase	 in	
genomic	content	at	an	early	stage.	Utilizing	in	vitro	culture	systems,	we	demonstrate	
that	 overexpression	 of	 Plk1	 leads	 to	 reduced	 proliferation	 and	 causes	 polyploidy.	
Time-lapse	imaging	of	mammary	organoid	cultures	and	mouse	embryonic	fibroblasts	
(MEFs)	 overexpressing	 Plk1	 revealed	 that	 the	 polyploid	 cells	 originate	 due	 to	
impaired	chromosome	segregation	as	well	as	a	failure	of	cytokinesis	occurring	during	
mitosis.	 Increased	 mitotic	 aberrations	 and	 supernumerary	 centrosomes	
accompanied	 these	defective	 cell	division	processes.	Mechanistically,	 the	observed	
phenotype	can	be	partially	attributed	to	decrease	of	Shugoshin	1	(Sgo1)	a	target	of	
Plk1,	which	is	responsible	for	maintaining	cohesion	at	the	centromeres	thus	holding	
the	 sister	 chromatids	 together	 prior	 to	 anaphase.	 Premature	 loss	 of	 Sgo1	 during	
prometaphase	caused	a	partial	or	complete	loss	of	cohesion.		
In	 this	 dissertation,	 we	 report	 that	 one	 of	 the	 major	 consequences	 of	 Plk1	
overexpression	 is	 a	 staggering	 tumor	 suppressive	 effect,	 although	 this	 does	 not	
necessarily	negate	the	possibility	that	Plk1	could	promote	tumor	development	under	
a	 different	 set	 of	 circumstances.	 Despite	 these	 findings,	 Plk1	 inhibition	 in	 human	
tumors	could	still	have	a	beneficial	outcome	because	the	kinase	is	indispensable	for	
cell	 division.	 This	 work	 is	 not	 aimed	 at	 discouraging	 further	 research	 on	 Plk1	
inhibitors;	rather	it	provides	a	testament	to	the	use	of	genetically	engineered	mouse	
models	 (GEMMs)	 that	 closely	 mimic	 human	 disease	 for	 pre-clinical	 testing.	 It	 is	
imperative	to	understand	the	molecular	mechanisms	and	cellular	processes	leading	
up	to	tumor	onset	prior	to	the	development	of	therapeutic	strategies.	
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Zusammenfassung	
Nach	allgemeiner	Auffassung	ist	die	Serin/Threonin-Proteinkinase	Polo-like-Kinase	1	
(dt.	 "Polo-ähnliche	 Kinase	 1",	 Plk1)	 eine	 der	 Hauptregulatoren	 des	 Zellzyklus.	
Überexpression	 der	 Plk1	 ist	 ein	 häufiges	Merkmal	 verschiedener	 Tumorarten	 und	
korreliert	 in	 Patienten	 normalerweise	 mit	 einer	 schlechten	 Prognose.	 Die	 genaue	
Funktion	 der	 Plk1	 während	 der	 Tumorentwicklung	 ist	 allerdings	 nur	 unzureichend	
bekannt.	 In	 dieser	 Arbeit	 untersuchen	 wir	 die	 Konsequenzen	 der	 Plk1	
Überexpression	in	vivo	mit	Hilfe	von	induzierbaren	Mausmodellen.		
Wir	 konnten	 feststellen,	 dass	 Plk1	 nicht	 als	 Onkogen	 agiert,	 sondern	 das	 die	
Überexpression	von	Plk1	vielmehr	eine	stark	tumorsuppressiven	auf	Her2-	oder	Kras-
positiven	Brustkrebstypen	hat.	
Des	 Weiteren	 waren	 Plk1-überexprimierende	 Tumoren	 sowohl	 durch	 eine	
Verdopplung	 des	 kompletten	 Genoms	 als	 auch	 ein	 verstärktes	 Auftreten	 von	
Aneuploidie	 gekennzeichnet.	 Histologische	 Untersuchungen	 der	 murinen	
Brustdrüsen	 noch	 vor	 der	 Tumorentstehung	 bestätigten	 schon	 in	 diesem	 frühen	
Stadium	einen	Zusammenhang	zwischen	der	Überexpression	von	Plk1	und	erhöhtem	
Genomgehalt.	
Durch	 den	 Einsatz	 von	 in	 vitro	 Kultursystemen	 konnten	 wir	 nachweisen,	 dass	
Überexpression	 der	 Plk1	 zu	 Polyploidie	 und	 einer	 verringerten	 Proliferation	 führt.	
Darüber	hinaus	konnten	wir	durch	Zeitraffer-Mikroskopie	(engl.	time-lapse	imaging)	
von	 Organoidkulturen	 aus	 Brustgewebe	 und	 murinen	 embryonalen	 Fibroblasten	
(MEFs)	 mit	 Plk1	 Überexpression	 zeigen,	 dass	 die	 polyploiden	 Zellen	 aufgrund	 von	
Fehlern	während	der	Mitose	entstehen,	etwa	bei	der	Trennung	der	Chromosomen	
oder	 der	 Zytokinese.	 Diese	 fehlerhaften	 Zellteilungen	 traten	 zusammen	 mit	 einer	
erhöhten	Anzahl	mitotischer	Anomalien	und	überzähliger	Chromosomen	auf.	
Der	 beobachtete	 Phänotyp	 lässt	 sich	 mechanistisch	 teilweise	 durch	 eine	
Verminderung	 des	 Shugoshin	 1	 (SGO1)	 Proteingehaltes	 an	 den	 Kinetochoren	
erklären.	Dieses	Protein	 ist	 für	den	Zusammenhalt	der	Zentromeren	und	damit	 für	
das	Zusammenbleiben	der	Schwesterchromatiden	vor	der	Anaphase	verantwortlich.	
Der	 zu	 frühe	Verlust	 von	 SGO1	 schon	während	der	 Prometaphase	 führte	 teilweise	
oder	vollständig	zum	Verlust	dieses	Zusammenhaltes.		
In	 dieser	 Doktorarbeit	 zeigen	wir	 den	 stark	 tumorsuppressiven	 Effekt	 als	 eine	 der	
bedeutendsten	 Konsequenzen	 von	 Plk1	 Überexpression,	 wobei	 dies	 nicht	
zwangsläufig	 die	Möglichkeit	 ausschließt,	 dass	 Plk1	 unter	 anderen	 Umständen	 die	
Tumorentwicklung	 begünstigen	 könnte.	 Trotz	 dieser	 Ergebnisse	 könnte	 auch	 eine	
gegen	Plk1	gerichtete	Behandlung	von	humanen	Tumoren	eine	vorteilhafte	Wirkung	
haben,	weil	die	Plk1	unverzichtbar	für	die	Zellteilung	ist.	
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Diese	Arbeit	hat	nicht	das	Ziel,	von	jeglichen	weiteren	Bemühungen	zur	Blockade	der	
Plk1	 abzuraten.	 Vielmehr	 soll	 sie	 den	 Nutzen	 von	 genetisch	 veränderten	
Mausmodellen	 (engl.	 genetically	 engineered	 mouse	 models,	 GEMMs)	 für	 die	
präklinische	 Forschung	 hervorheben,	 die	 humane	 Krankheiten	 präzise	 nachahmen.	
Es	 ist	 zwingend	notwendig,	die	molekularen	Mechanismen	und	zellulären	Prozesse	
der	Tumorentstehung	zu	verstehen,	bevor	man	Therapiestrategien	entwickelt.				 	
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Introduction	  
Polo-like	Kinase	1	(Plk1)	
1.1	Plk1	Discovery,	Structure	and	Function	
Polo-like	kinase	is	a	serine	threonine	protein	kinase,	ordained	as	one	of	the	master	
regulators	of	 cell	 cycle.	The	gene	encoding	 for	Plk1	was	 first	discovered	over	 forty	
years	ago	in	yeast,	by	screening	for	mutants	defective	in	cell	division	(Hartwell	et	al.,	
1973).	 Plk1	 gets	 its	 unique	name	because	 cells	 lacking	 this	 kinase	display	 a	 strong	
tendency	to	form	a	monopolar	spindle	with	the	chromosomes	arranged	in	a	circular	
manner	resembling	the	shape	of	a	Polo.	This	was	first	observed	in	Drosophila	(Sunkel	
and	Glover,	1988).	In	humans,	Plk1	is	a	conserved	member	of	a	family	of	four	related	
kinases,	 each	 with	 varied	 yet	 unrelated	 functions	 (Van	 De	 Weerdt	 and	 Medema,	
2006).		
The	 protein	 is	 composed	 of	 603	 amino	 acids	 and	 structurally	 it	 includes	 a	 kinase	
domain	 (KD)	 at	 the	 N-terminal	 plus	 two	 conserved	 regions	 termed	 as	 polo-box	
domains	 (PBD)	 located	 at	 the	 C-terminal	 (Fig1.1).	 While	 the	 kinase	 domain	 is	
essential	 for	 the	 functional	 activity	 of	 the	 kinase,	 the	 PBDs	 are	 responsible	 for	
mediating	subcellular	 localization,	protein	 interactions	as	well	as	exertion	of	partial	
control	over	the	N-terminal	kinase	activity	(Cheng	et	al.,	2003).		
a
b 
 
Fig1.1:	 (a)	 Basic	 structure	of	 Plk1	 showing	 the	PBD	at	 the	C-terminal	 and	KD	at	 the	N-terminal.	 (b)	
Schematic	of	Plk1	activity	(Archambault,	Lépine	and	Kachaner,	2015).	
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The	 basic	 functioning	 of	 the	 kinase	 is	 illustrated	 by	 the	 simple	 schematic	 shown	
above	(Fig1.1b).	The	polo-box	domain	recognizes	and	binds	to	a	protein	(X)	that	has	
been	primed	by	another	kinase	via	phosphorylation	at	a	certain	site,	following	which	
the	kinase	domain	of	Plk1	can	then	phosphorylate	the	same	protein	at	another	motif	
or	interact	with	a	separate	protein	(Y)	in	the	region.	The	KD	and	PBD	can	also	inhibit	
each	 other	 via	 intramolecular	 interaction.	 This	 mode	 of	 action	 allows	 for	 Plk1	 to	
change	 localization	 and	 to	 exert	 considerable	 amount	 of	 control	 over	 several	
different	 targets	 during	mitotic	 progression	 (Lee	et	 al.,	 1998;	 Archambault,	 Lépine	
and	Kachaner,	2015).	
1.2	Mitotic	regulation	by	Plk1	
Plk1	 is	 regarded	 to	be	 just	as	 important	as	 the	Cyclins	and	Cdks	when	 it	 comes	 to	
mitotic	 regulation.	 The	 roles	of	 Plk1	 in	mitosis	 range	 from	 transition	of	G2	 into	M	
phase	all	the	way	up	to	cytokinesis.	One	of	the	most	interesting	aspects	of	Plk1	is	the	
ability	to	change	subcellular	localization	as	per	functional	needs	during	cell	division;	
the	mechanism	by	which	the	kinase	achieves	this	feat	was	discussed	in	the	previous	
section.	The	localization	of	Plk1	at	different	phases	of	mitosis	and	its	broad	functions	
are	shown	in	Fig1.2.	Activation	of	Plk1	is	achieved	by	the	phosphorylation	at	the	T-
loop	(Thr210)	by	Aurora	kinase	at	the	start	of	the	G2	phase,	 it	 is	also	 important	to	
note	the	co-factor	Bora	is	essential	for	this	step	(Seki,	Coppinger	and	Jang,	2008).		
 
Fig1.2:	Functions	and	localization	of	Plk1	(green)	during	different	phases	of	mitosis	(Petronczki,	Lenart	
and	Peters,	2008).	
Once	activated,	Plk1	 localizes	at	the	centrosomes	and	facilitates	transition	from	G2	
to	M	by	 phosphorylation	 of	 cyclin	 B1	 facilitating	 its	 translocation	 into	 the	 nucleus	
thereby	signaling	the	start	of	mitosis	(Toyoshima-Morimoto	et	al.,	2001).	One	of	the	
most	important	functions	of	Plk1	during	prophase	is	centrosome	maturation,	which	
is	 in	 turn	 a	 prerequisite	 for	 nucleation	 of	 microtubules	 and	 the	 subsequent	
formation	of	the	spindle.	Plk1	assists	in	centrosome	maturation	by	phosphorylation	
of	centrosomal	protein	Nlp,	which	 indirectly	facilitates	the	recruitment	of	γ	tubulin	
complexes	 to	 the	 centrosome	 (Casenghi	 M,	 Meraldi	 P,	 Weinhart	 U,	 Duncan	 PI,	
Körner	R,	Nigg,	2003).		
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Following	nuclear	envelope	breakdown	(NEBD)	there	is	an	increase	in	Plk1	levels	at	
the	 kinetochores;	 this	 has	 been	 mainly	 attributed	 to	 mediating	 kinetochore-
microtubule	 (K-MT)	 attachment,	 since	 the	 strong	 staining	 is	 observed	 up	 until	
alignment	of	 the	chromosomes.	Studies	have	verified	 the	 link	Plk1	shares	with	 the	
spindle	 assembly	 checkpoint	 (SAC),	 confirming	 the	 presence	 of	 increased	 levels	 of	
the	 protein	 at	 unattached	 kinetochores.	 The	 SAC	 is	 primarily	 responsible	 for	
preventing	transition	into	anaphase	till	all	kinetochores	are	attached	to	the	spindle.	
Furthermore,	 one	 of	 the	 targets	 of	 Plk1	 during	 this	 phase	 is	 BubR1	 an	 important	
component	 of	 the	 SAC.	 It	 has	 been	 proven	 that	 this	 phosphorylation	 of	 BubR1	 is	
essential	for	maintaining	the	stability	of	K-MT	attachments	(Elowe	et	al.,	2007).		
Plk1	also	partakes	in	the	disruption	of	sister	chromatid	cohesion	prior	to	anaphase;	
this	will	 be	 discussed	 elaborately	 in	 the	 following	 section.	 Early	 studies	 describing	
the	 functions	 of	 Plk1	 were	 performed	 by	 complete	 inhibition	 or	 knockouts,	 this	
inadvertently	led	to	the	SAC	mediated	arrest	of	these	cells	at	prometaphase	(Sunkel	
and	Glover,	1988;	Kishi	et	al.,	2009).	Hence	much	was	not	known	about	the	functions	
of	 Plk1	during	 anaphase	 and	 telophase,	 however	 the	 localization	of	 the	protein	 at	
the	middle	of	the	spindle	in	anaphase	suggests	a	role	in	mediating	the	formation	of	
the	 cleavage	 furrow	 and	 cytokinesis.	 Recent	 studies	 have	 been	 able	 to	 show	 that	
Plk1	indeed	has	a	vital	function	in	cytokinesis	(Burkard	et	al.,	2007;	Kim	et	al.,	2014),	
this	is	explained	in	more	detail	in	the	upcoming	sections.	
1.3	Plk1	and	Cohesion	
Cohesion	in	this	case	refers	to	the	protein	complex	that	holds	the	sister	chromatids	
together	before	the	start	of	anaphase.	It	is	also	responsible	for	the	typical	X	shaped	
appearance	 of	 the	 chromosomes.	 Majority	 of	 the	 cohesion	 is	 removed	 from	 the	
chromatin	 early	 on	 in	 mitosis	 to	 allow	 the	 formation	 of	 the	 sister	 chromatids,	
however	 cohesion	 is	 still	 retained	mainly	 at	 the	 centromeres	 (Losada,	 Hirano	 and	
Hirano,	2002).	 This	 cohesion	 complex	 is	protected	by	another	protein	Shugoshin	1	
(Sgo1)	 also	 dubbed	 as	 the	 guardian	 of	 cohesion	 (Kitajima	 et	 al.,	 2006),	 which	 is	
recruited	to	the	centromere	at	the	late	G2	phase	(Perera	and	Taylor,	2010).		
Plk1	 affects	 cohesion	 by	 a	 twofold	 mechanism,	 first	 it	 phosphorylates	 Sgo1	
effectively	removing	it	from	its	centromeric	localization	prior	to	anaphase	(Shintomi	
and	Hirano,	2010).	Plk1	also	directly	phosphorylates	cohesion	subunits	SA2	and	Scc1.	
Phosphorylation	of	the	SA2	subunit	results	in	reduced	affinity	to	chromatin,	which	is	
essential	 for	 the	 removal	 of	 cohesion	 from	 the	 arms	 following	 prophase	 (Fig1.3).	
While	the	phosphorylation	of	Scc2	assists	cohesion	cleavage	by	Separase	during	the	
transition	from	metaphase	to	anaphase	(Hornig	and	Uhlmann,	2004).		
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Fig1.3:	 Schematic	 diagram	 displaying	 maintenance	 of	 cohesion	 till	 anaphase.	 Plk1	 mediated	
phosphorylation	is	responsible	for	displacing	centromeric	Sgo1	and	releasing	arm	cohesion	(Hu	et	al.,	
2007).	
1.4	Cytokinesis	and	the	roles	of	Plk1	
The	final	stage	of	mitosis,	which	results	in	two	independent	daughter	cells,	is	called	
cytokinesis.	This	process	is	initiated	at	the	end	of	anaphase	and	it	 is	marked	by	the	
formation	 of	 a	 cleavage	 furrow	 in	 between	 the	 separated	 nuclear	 material.	 The	
ingression	of	 the	 cleavage	 furrow	 is	 controlled	by	an	actin-myosin	 contractile	 ring.	
There	 are	 two	 essential	 steps	 leading	 to	 successful	 cytokinesis,	 the	 first	 is	 the	
formation	of	 the	 contractile	 ring	 at	 the	 start	 of	 the	process	 and	 the	 second	 is	 the	
assembly	of	the	abscission	complex	at	the	end	of	the	process.	Plk1	is	linked	to	both	
these	mandatory	steps.		
The	formation	and	functioning	of	the	contractile	ring	requires	the	accumulation	and	
activation	of	the	RhoA	GTPase	at	the	equatorial	cortex.	Although	Plk1	is	not	essential	
for	 the	 recruitment	 of	 RhoA,	 it	 was	 shown	 that	 Plk1	was	 required	 for	 the	 proper	
localization	of	important	RhoA	activation	factor,	the	GEF	protein	Ect2	(Burkard	et	al.,	
2007;	Petronczki,	Lenart	and	Peters,	2008).		
For	abscission	to	occur	properly	at	the	end	of	cytokinesis,	the	ESCRT	complex	must	
be	 assembled.	 The	 localization	 of	 the	 protein	 Cep55	 to	midbody	 after	 the	 end	 of	
anaphase	triggers	this	process.	The	phosphorylation	of	Cep55	by	Plk1	prevents	the	
premature	 localization	 to	 the	 midbody,	 effectively	 controlling	 the	 timing	 of	
abscission	 (Carmena,	 2012).	 Thus,	 Plk1	 exerts	 control	 over	 the	 start	 and	 end	 of	
cytokinesis.	
	5	
	
1.5	Plk1	and	CIN	in	Tumors	
Chromosomal	 instability	 (CIN)	 is	one	of	 the	prominent	hallmarks	of	human	cancer,	
which	 is	 linked	with	poor	patient	 survival.	 It	 is	an	ongoing	process	by	which	either	
whole	or	parts	of	chromosomes	are	gained	or	lost.	CIN	is	known	to	promote	tumor	
evolution	and	drives	resistance	to	therapy	(Godek	et	al.,	2016;	Rowald	et	al.,	2016;	
López-García	et	al.,	2017).	Overexpression	of	certain	genes	are	commonly	associated	
with	CIN,	 this	 is	aptly	dubbed	as	 the	CIN70	signature	 (Carter	et	al.,	2006).	Most	of	
these	 genes	 control	 vital	 processes	 occurring	 during	 cell	 division.	 As	 such	
overexpression	 of	 the	 individual	 genes	 that	 are	 a	 part	 of	 the	 CIN70	 in	 an	
experimental	context	lead	to	spontaneous	tumor	initiation	(Sotillo	et	al.,	2007;	Nam	
and	Van	Deursen,	2014).	Plk1	is	also	a	part	of	this	infamous	CIN70	gene	signature. 
Overexpression	of	Plk1	is	a	common	occurrence	observed	in	several	different	types	
of	human	tumors	and	 it	usually	correlates	with	bad	prognosis	 in	patients	 (Eckerdt,	
Yuan	and	Strebhardt,	2005).	Plk1	overexpression	has	also	been	implicated	to	play	an	
early	 stage	 role	 in	 the	 development	 of	 certain	 carcinomas	 (Ito	 et	 al.,	 2004).	
Furthermore,	 Plk1	 is	 a	 known	 antagonist	 of	 the	 prominent	 tumor	 suppressor	 p53	
(Ando	et	al.,	2004;	Liu	et	al.,	2010).		
Considering	these	factors	plus	the	 importance	of	Plk1	 in	cell	division	and	adding	to	
this	the	fact	that	it	 is	an	easily	druggable	kinase,	all	make	it	an	attractive	target	for	
anticancer	therapy.	Hence	this	has	led	to	the	development	of	several	small	molecule	
inhibitors	 for	 Plk1,	 among	 these	 BI2536	 is	 known	 to	 inhibit	 Plk1	 with	 higher	
specificity	and	is	considered	for	treatment	against	leukemia	and	non-small	cell	lung	
cancer	 (Lénárt	et	al.,	 2007;	 Steegmaier	et	al.,	 2007;	Medema,	 Lin	 and	Yang,	 2011;	
Choi	et	al.,	2015;	Gutteridge	et	al.,	2016).		
Despite	 reasonable	 success	 using	 this	 inhibitor,	 the	 causative	 role	 of	 Plk1	 in	
tumorigenesis	 is	 still	 under	 debate.	 Due	 to	 the	 highly	 proliferative	 nature	 of	 the	
tumors	and	the	fact	that	Plk1	levels	are	cell	cycle	dependent,	it	has	been	argued	that	
Plk1	 overexpression	 is	merely	 a	 consequence	 of	 increased	 proliferation	 caused	 by	
oncogenic	 transformation	 (Cholewa,	 Liu	 and	 Ahmad,	 2013).	 The	 role	 of	 Plk1	 in	
neoplastic	 transformation	 and	 tumor	 development	 has	 yet	 to	 be	 completely	
deduced.	
Cancer		
1.6	Whole	Genome	Doubling	in	Tumorigenesis	
According	 to	 recent	 studies,	 a	 staggering	 20%	 of	 all	 human	 tumors	 display	 near	
tetraploid	 karyotypes	 and	 whole	 genome	 doubling	 events	 during	 tumor	
development	have	occurred	 in	 roughly	37%	of	 tumors,	 including	 those	with	a	near	
diploid	 karyotype	 (Dewhurst	 et	 al.,	 2014).	 Tetraploid	 cells,	 directly	 resulting	 from	
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genome	doubling	events	have	been	observed	in	early	stages	of	solid	tumors	even	in	
very	preliminary	histological	studies	(Kirkland,	1966).	A	p53	dependent	mechanism	is	
usual	in	place	to	halt	the	proliferation	of	these	potentially	oncogenic	tetraploid	cells	
(Ganem	and	Pellman,	2007).		
Tetraploidization	 in	a	tumor	context	can	be	caused	by	several	 independent	events,	
prominent	among	them	are	 faulty	chromosome	segregation	due	to	mitotic	defects	
or	 cytokinesis	 failure,	 cell	 fusion	 and	 chromosome	 endoreduplication	 (Fig1.4).	
Cytokinesis	 failure	 in	 p53	 deficient	 cells	 is	 enough	 to	 promote	 tumorigenesis	
whereas	 in	 p53	 proficient	 cells	 it	 leads	 to	 the	 activation	 of	 the	 Hippo	 tumor	
suppressor	 pathway	 (Fujiwara	et	 al.,	 2005;	Ganem	et	 al.,	 2014).	 Surprisingly,	 even	
tumors	with	 an	 intact	 p53	 function	 can	undergo	 genome	doubling	 and	maintain	 a	
tetraploid	 karyotype.	 This	 is	 due	 to	 a	 mechanism	 of	 tolerance	 driven	 by	 cyclin	 D	
overexpression	at	the	early	stages	of	tumor	development	(Crockford	et	al.,	2017).		
Whole	 genome	doubling	 has	 also	 been	 shown	 to	 be	 a	 prominent	 driver	 of	 cancer	
genome	evolution	by	promoting	CIN.	Tetraploid	cells	demonstrate	a	better	tolerance	
towards	 chromosomal	 aberrations,	 which	 allows	 for	 the	 accumulation	 of	 several	
genetic	alterations	over	time,	eventually	leading	to	tumorigenesis	or	development	of	
resistant	clones	(Dewhurst	et	al.,	2014).	
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Fig1.4:	 Schematic	 showing	 the	 main	 mechanisms	 of	 tetraploidization	 in	 tumors	 and	 the	 causative	
factors	for	each	mechanism.	“Abbreviations:	ATM/ATR,	ataxia	telangiectasia	mutated/ATM	and	Rad3-
related;	 Cdk,	 cyclin-dependent	 kinase;	 Cyc,	 cyclin;	 LATS1,	 large	 tumor	 suppressor	 1;	Mad2,	mitotic	
arrest	deficient	2;	OE,	overexpression.”	(Davoli,	de	Lange	and	Lange,	2011).	
1.7	Breast	Cancer	
Breast	cancer	is	responsible	for	one	of	the	highest	cancer	related	mortality	rates	in	
women	 worldwide.	 Besides	 the	 usual	 cancer	 risk	 factors,	 women	 who	 are	 post	
menopause,	 had	 children	 late	 and	 those	 who	 underwent	 hormone	 replacement	
therapy	have	a	higher	 risk	of	breast	cancer	 (Siegel,	Miller	and	 Jemal,	2015).	Hence	
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specific	 screening	 of	 females	 of	 the	 age	 group	 40-70	 has	 proven	 to	 be	 beneficial,	
helping	early	detection	of	the	disease	(Nelson	et	al.,	2009).	Approximately	5-10%	of	
all	 breast	 cancer	 cases	 are	 also	 attributed	 to	 inherited	 genetic	 traits,	 this	 includes	
mutations	in	BRCA1	and	BRCA2.	The	five-year	survival	rate	of	women	diagnosed	with	
breast	cancer	in	developed	countries	is	as	high	as	80-90%,	however	the	disease	still	
claimed	 the	 lives	 of	 522,000	 women	 worldwide	 in	 the	 year	 2012	 (World	 Cancer	
Report	2014).	
Most	breast	cancer	related	mortality	is	not	due	to	the	primary	tumor	but	caused	by	
metastasis	of	the	tumor	cells	mainly	to	the	lung,	brain	or	the	bone.	Early	detection	of	
the	disease	is	paramount	in	stopping	metastasis.	Breast	cancer	is	detected	mainly	by	
mammography	and	the	diagnosis	is	confirmed	by	the	biopsy	of	the	abnormal	growth	
(Nelson	 et	 al.,	 2009).	 Once	 detected,	 the	 normal	 mode	 of	 treatment	 is	 surgical	
removal	 of	 the	 tumor	 and	 the	 surrounding	 region.	 This	 is	 accomplished	 either	 by	
lumpectomy	which	is	the	removal	of	a	small	region	of	the	breast	or	the	entire	breast	
is	removed	by	mastectomy.	The	exact	surgical	procedure	is	determined	on	a	case-by-
case	 basis	 based	 on	 the	 size	 and	 staging	 of	 the	 tumor.	 The	 treatment	 takes	 a	
multidisciplinary	 approach	 to	 reduce	 the	 chance	of	 remission,	 therefore	 surgery	 is	
usually	 followed	 by	 radiotherapy,	 chemotherapy,	 hormone-blocking	 therapy	 or	
targeted	 therapy	 (Saini	 et	 al.,	 2012).	 The	 second	 line	 treatment	 is	 determined	
primarily	by	the	receptor	status	of	the	tumor,	deduced	by	immunohistochemistry	of	
the	 tumor	 biopsy.	 If	 the	 cancer	 cells	 express	 the	 estrogen	 receptor	 (ER)	 or	
progesterone	 receptor	 (PR),	 since	 they	 depend	 on	 that	 hormone	 for	 their	
proliferation,	they	can	be	treated	using	drugs	that	block	the	effect	on	the	hormone	
(Burstein	et	al.,	2014).	A	good	example	of	this	is	the	treatment	of	ER	positive	tumors	
with	 tamoxifen.	The	 tumors	 that	are	positive	 for	 the	Her2	receptor	can	be	 treated	
with	 trastuzumab	which	 is	 a	monoclonal	 antibody	 or	 lapatinib	which	 is	 a	 tyrosine	
kinase	inhibitor	(Moasser	and	Krop,	2015;	Goel	et	al.,	2016).	
The	breast	 is	 also	one	of	 the	 tissues	 that	 is	most	 susceptible	 to	 cancer	due	 to	 the	
constant	cycles	of	cell	proliferation	and	death	driven	by	the	hormonal	fluctuations	of	
the	estrous	cycle	(Visvader	and	Stingl,	2014).	The	high	rate	cell	turnover	increase	the	
chance	 of	 chromosomal	 aberrations	 or	 erroneous	 DNA	 replication,	 thereby	 also	
increasing	cancer	risk	(Ashford	et	al.,	2015).	
1.8	Modelling	Breast	Cancer	in	Mice	
Genetically	 engineered	 mouse	 models	 (GEMMs)	 are	 a	 valuable	 resource	 for	
dissecting	the	molecular	mechanisms	behind	tumorigenesis.	A	necessary	solution	to	
circumvent	 the	 limitations	 of	 studies	 using	 primary	 patient	 material.	 By	 closely	
mimicking	 the	 human	 disease,	 GEMMs	 allow	 us	 to	 study	 tumor	 initiation,	
progression	and	provide	a	platform	to	test	new	treatment	methods	(Menezes	et	al.,	
2014).		
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There	are	many	approaches	for	the	development	of	transgenic	mouse	models,	one	
of	the	most	prevalent	methods	is	the	random	integration	of	the	gene	of	interest	into	
the	germline	of	the	mouse,	achieved	by	injecting	the	DNA	directly	into	the	pronuclei	
of	the	fertilized	egg	(Cho,	Haruyama	and	Kulkarni,	2009).	This	method	was	used	to	
identify	 potential	 oncogenes	 and	 drivers	 of	 breast	 cancer	 by	 utilizing	 the	 breast	
tissue	 specific	 MMTV	 (mouse	 mammary	 tumor	 virus)	 promoter	 to	 control	
transcription	(Wang	et	al.,	1994).	Since	some	of	these	genes	proved	to	be	embryonic	
lethal	and	owing	to	the	fact	that	breast	cancer	is	mainly	a	disease	observed	in	adults	
of	 the	 species,	 it	 also	became	essential	 to	control	 the	 timing	of	 induction	of	 these	
genes.	This	conundrum	led	to	the	development	of	mouse	models	with	the	possibility	
to	selectively	 induce	expression	of	 the	 transgene	 in	a	 time-controlled	manner.	The	
most	 prominent	 among	 these	 models	 is	 the	 tetracycline	 inducible	 system	 (Tet-
ON/Tet-OFF).	 The	 mode	 of	 action	 of	 this	 system	 is	 described	 in	 figure1.5	 shown	
below.	Thus,	the	MMTV-rtTA	and	MMTV-tTA	systems	were	established	to	selectively	
induce	 the	 expression	 of	 transgenes	 in	 the	 mammary	 glands	 and	 monitor	 their	
oncogenic	potential	(Boxer	et	al.,	2004).	
 
Fig1.5:	 Tetracycline	 inducible	 system	 and	 the	 mode	 of	 operation.	 Tet-ON:	 The	 expression	 of	 the	
transgene	 is	 induced	 in	 the	presence	of	 tetracycline	or	 its	analog	doxycycline.	Tetracycline	binds	 to	
the	transcription	factor	rtTA	this	in	turn	binds	to	the	promoter	region	inducing	gene	expression.	Tet-
OFF:	 Expression	 of	 transgene	 is	 inhibited	 in	 the	 presence	 of	 tetracycline	 or	 its	 analog.	 Tetracycline	
binds	 to	 transcription	 factor	 tTA	 preventing	 its	 association	 with	 the	 promoter	 region,	 effectively	
switching	off	gene	expression.	Figure	source:	https://www.genoway.com.	
Due	to	the	sheer	number	of	different	mouse	models	currently	in	use	to	study	cancer,	
I	will	 limit	 the	 rest	of	 this	 section	only	 to	briefly	describe	 those	models,	which	are	
relevant	for	understanding	this	project.	
Overexpression	of	the	Her2	receptor	due	to	the	amplification	of	the	corresponding	
gene	 ERBB2	 is	 prevalent	 in	 25%	 of	 all	 cases	 of	 human	 breast	 cancer.	 Her2	 is	 a	
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member	 of	 the	 EGFR	 receptor	 family	 and	 is	 as	 such	 responsible	 for	 promoting	
proliferation	 and	 survival	 by	 downstream	 signaling	 through	 MAPK	 and	 PI3K-AKT	
pathways	respectively	(Rexer	and	Arteaga,	2012).	The	conditional	overexpression	of	
Her2	using	a	tetracycline-inducible	mouse	model	system,	led	to	the	development	of	
mammary	tumors	in	the	entire	colony,	with	an	average	latency	of	42	days.	Oncogene	
withdrawal	by	removal	of	doxycycline,	caused	the	complete	regression	of	tumors	in	
all	 the	animals,	however	relapse	of	the	tumor	was	observed	 in	64%	of	the	animals	
several	months	post	treatment	(Moody	et	al.,	2002).	
Although	 the	 Ras	 family	 of	 genes	 is	 frequently	mutated	 in	 cancer	 (32%),	 it	 is	 only	
observed	 to	 be	 the	 case	 in	 7%	 of	 breast	 cancer	 patients	 with	 Kras	 mutations	
contributing	 to	 4%	 of	 the	 cases	 (O’Hagan	 and	 Heyer,	 2011;	 Pylayeva-Gupta,	
Grabocka	 and	 Bar-Sagi,	 2011).	 This	 can	 be	 attributed	 to	 the	 frequently	 observed	
overexpression	of	Her2	in	breast	cancer.	Since	Her2	is	upstream	of	Ras	in	the	same	
pathway,	 cancer	 cells	 have	 no	 further	 requirement	 to	 modify	 this	 pathway	
(Pylayeva-Gupta,	Grabocka	 and	Bar-Sagi,	 2011).	 Even	 though	Kras	mutations	 are	 a	
relatively	minor	 occurrence	 in	 breast	 cancer,	 nevertheless	 a	 tetracycline	 inducible	
mouse	model	was	developed	to	study	Kras	as	a	driver	of	mammary	tumorigenesis.	
These	 mice	 developed	 mammary	 tumors	 with	 an	 average	 latency	 of	 154	 days	
(Podsypanina	et	al.,	2008).	
In	vitro	Model	Systems	
1.9	Mammary	Organoids	
The	advent	of	mouse	models	has	provided	us	with	a	valuable	tool	 for	studying	the	
events	 that	 lead	 to	 transformation.	 However,	 understanding	 certain	 cellular	
processes	is	beyond	the	scope	of	just	utilizing	mouse	model	systems.	Traditional	cell	
culture	techniques	do	not	provide	an	accurate	representation	of	the	in	vivo	organism	
and	this	has	led	to	the	development	of	3-dimensional	culture	systems.	
3D	 organotypic	 culture	 systems	 or	 organoids	 have	 been	 utilized	 to	 study	 cell-cell	
interactions,	 tissue	 development,	 signaling	 as	 well	 as	 effect	 of	 drugs.	 These	 3D	
cultures	can	be	established	from	single	epithelial	cells	obtained	from	various	tissues	
(Shamir	and	Ewald,	2014).	 In	a	normal	mammary	gland,	 cells	differentiate	 to	 form	
acini	and	ducts	which	are	responsible	for	milk	production	and	delivery	(Visvader	and	
Stingl,	 2014).	 To	 recapitulate	 this	 process	 in	 vitro,	 extra	 cellular	 matrix	 molecules	
with	 basement	 membrane	 proteins	 are	 required.	 Matrigel,	 which	 is	 a	 gelatinous	
membrane	protein	secreted	by	EHS	mouse	sarcoma	cells	 is	commonly	utilized	as	a	
substitute	 to	 fulfil	 this	 requirement.	 When	 single	 mammary	 epithelial	 cells	 are	
seeded	 in	Matrigel,	 they	develop	to	 form	hollow	spherical	 structures	which	closely	
resemble	the	mammary	gland	acini	(Petersen	et	al.,	1992).	
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A	 new	 approach	 for	 studying	 the	 effects	 of	 oncogenic	 transformation	 in	 vitro	
combines	MMTV-rtTA	tetracycline	inducible	mouse	models	and	organotypic	culture	
systems.	Using	mammary	cells	 from	these	mouse	models	 to	develop	organoids,	an	
inducible	in	vitro	system	to	monitor	the	effects	of	oncogene	induction	over	time,	has	
been	established.	With	the	induction	of	the	oncogenes,	epithelial	cells	loose	polarity	
and	 the	 rapidly	dividing	cells	eventual	 lead	 to	 the	 filling	up	of	 the	hollow	acini-like	
spheres.	These	events	closely	mimic	the	progression	of	invasive	ductal	carcinoma	in	
humans	(Jechlinger,	Podsypanina	and	Varmus,	2009).	
Objectives	
This	work	was	primarily	 conceived	 to	 investigate	 the	 in	 vivo	 consequences	of	 Plk1	
overexpression	during	 tumorigenesis.	We	utilized	 inducible	GEMMs	to	monitor	 the	
oncogenic	 potential	 of	 Plk1	 as	well	 as	 study	 the	 effects	 of	 elevated	 Plk1	 levels	 on	
Her2	 or	 Kras	 driven	 breast	 cancer.	 The	 bulk	 of	 the	 initial	work	was	 the	 functional	
characterization	of	Plk1	overexpression	 in	vivo	 in	 the	mammary	gland	prior	 to	and	
following	 tumor	 onset.	 The	 second	part	was	 focused	 on	 elucidating	 the	molecular	
mechanisms	leading	to	the	observed	phenotypes	using	in	vitro	culture	systems.	With	
this	 under	 consideration,	 the	 main	 objectives	 of	 this	 study	 can	 be	 broadly	
categorized	as	follows:	
Ø Study	 the	 impact	 of	 Plk1	 overexpression	 on	 tumorigenesis	 using	 inducible	
mouse	models.	
Ø Understand	the	molecular	mechanisms	and	cellular	processes	that	contribute	
to	the	observed	phenotype.	
Ø Explore	 the	 effect	 of	 Plk1	 overexpression	 on	 mitosis	 and	 chromosome	
segregation.	
Ø Elucidate	the	consequences	of	Plk1	induced	polyploidy	on	tumor	physiology.	
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Materials	and	Methods	
In	vivo	Mouse	Models	
2.1	Generation	of	GEMMs	
Mouse	models	utilized	during	the	study	were	generated	using	KH2	ES	cells	provided	
by	Konrad	Hochedlinger	and	Rudolf	Jaenisch	(Beard	et	al,	2006).	FLAG	tagged	human	
Plk1	 cDNA	 cassette	 under	 the	 control	 of	 the	 tetracycline	 response	 element	 (tetO	
minimal	promoter)	was	inserted	at	the	ColA1	locus	of	the	KH2	ES	cells	(Figure	2.1).	
These	ES	cells	also	contained	the	M2-rtTA	gene	inserted	within	the	Rosa26	allele	for	
the	 ubiquitous	 expression	 of	 the	 Plk1	 transgene.	 The	 Malumbres	 laboratory	 (Cell	
Division	and	Cancer	Group,	CNIO)	carried	out	the	generation	of	ColA1-Plk1	animals.	
These	 animals	 were	 then	 crossed	 with	 MMTV-rtTA	 (Gunther	 et	 al,	 2002),	 TetO-
KrasG12D	 (Fisher	 et	 al,	 2001),	 TetO-rat-Her2	 (Moody	 et	 al,	 2002),	 and	 H2B-GFP	
(Hadjantonakis	&	Papaioannou,	2004)	animal	models.			
	
Figure	 2.1:	 Schematic	 representation	 of	 alleles,	 cassette	 containing	 the	 human	 FLAG-Plk1	 cDNA	
downstream	 of	 the	 tetO	 sequences	 is	 inserted	 in	 the	 ColA1	 locus	 via	 FLP-FRT	 system,	 after	
homologous	recombination	 in	KH2	ES	cells.	Flippase	(Flp)	recombinase	works	by	recognizing	the	Flp	
recombinase	 target	 (FRT)	 sequences	 flanking	 the	 region	 of	 interest.	 The	 ES	 cells	 are	 then	 selected	
using	a	hygromycin	resistance	cassette	downstream	of	the	insert.	This	allele	ColA1-Plk1	is	combined	
with	the	Rosa26-rtTA	allele	expressing	the	tetracycline	transactivator.	
2.2	Animal	Husbandry	and	Monitoring	of	Disease	
	The	mice	for	the	study	were	housed	in	a	specific	pathogen	free	(SPF)	environment	
with	12hr	day-night	cycles,	average	temperature	of	21°C	and	humidity	maintained	at	
55%.	 All	 breeding	 and	 experimental	 procedures	were	 carried	 out	 at	 the	DKFZ	 and	
EMBL	Mouse	Biology	Unit.	Procedures	were	in	accordance	with	European	Parliament	
directive	(2010/63/EU)	on	protection	of	animals	used	for	scientific	purposes,	current	
Italian	legislation	(Art.	9,	27.	Jan	1992,	no116)	and	the	German	Animal	Welfare	Act	
ColA1(Plk1/Plk1) 
Rosa26(rtTA/rtTA) 
Hyg*-pA ColA1 
PGK-ATG 
FLAG-Plk1 
Hyg-pA ColA1 SA-pA tetO pA 
ColA1 locus 
    in KH2 ES cells 
PGK-ATG 
SA-pA 
FLAG-Plk1 
tetO 
pA Targeting vector 
Flp recombinase 
pA 
pA 
ColA1(Plk1) 
Rosa26(rtTA) 
Rosa26 rtTA ColA1(+/ lk1)
Rosa26(+/rtTA)
olA1 locus
in KH  ES cells
lA1(Plk1)
R 26(rtTA)
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(TierSchG,	 1972)	 in	 addition	 to	 Animal	 Protection	 Laboratory	 Animal	 Regulations,	
2013.	In	vivo	induction	of	transgenes	in	adult	female	mice	(8-10	weeks)	was	achieved	
using	 food	 pellets	 (625	 mg/kg,	 Harlan-Teklad)	 containing	 doxycycline	 (stable	
tetracycline	 analogue).	 Experimental	 animals	 were	 monitored	 everyday	 by	
specialized	technicians	at	the	respective	animal	facilities.	Progression	of	tumors	was	
checked	twice	a	week	after	tumor	incidence	and	measurements	were	done	using	a	
vernier	 caliper.	 Human	 end	 point	 was	 determined	 when	 overall	 tumor	 volume	
reached	or	 exceeded	1.5	 cm,	mice	were	 sacrificed	by	 cervical	 dislocation.	All	mice	
were	maintained	in	a	mixed	FVB	and	C57BL/6J	background.	
2.3	Mouse	Estrous	Cycle	
Pap	smears	were	performed	to	check	the	estrous	phase	of	 the	mouse.	The	vaginal	
lavage	was	done	by	carefully	pipetting	50µl	of	1x	PBS	 into	 the	vaginal	canal	of	 the	
mouse;	 the	 resuspended	 cells	were	 spread	 onto	 a	 superfrost	 slide	 and	 allowed	 to	
dry.	 Crystal	 Violet	 (Sigma)	 staining	 was	 done	 for	 1	 min	 followed	 by	 2-3	 min	 of	
washing	with	water;	the	slides	were	then	air	dried	and	viewed	under	a	microscope.	
 
 
Figure	2.2:	Cytological	classification	of	pap	smears	as	observed	during	different	phases	of	the	mouse	
estrous	cycle	(Aliagas	et	al.	2010).	
2.4	Animal	Necropsy	
Necropsy	 tools	 and	 Styrofoam	 surface	were	 disinfected	with	 70%	 ethanol	 prior	 to	
procedure.	 Mice	 were	 sacrificed	 by	 cervical	 dislocation	 and	 fixed	 in	 an	 upright	
position	on	 the	 surface	using	pins.	A	 vertical	 incision	 running	across	 the	body	was	
made	 and	 the	 skin	was	 pulled	 and	 pinned	 as	 displayed	 (Figure	 2.3).	 All	mammary	
glands	were	inspected	prior	to	excision	and	any	abnormal	features	were	noted.	The	
tissue	 samples	were	 either	 collected	 in	 10%	 neutral	 buffered	 formalin	 (Sigma)	 for	
histological	 processing	 or	 snap	 frozen	 with	 liquid	 nitrogen	 for	 DNA/RNA/protein	
work.	
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Figure	2.3:	Necropsy	of	adult	female	mouse,	labeling	shows	
the	position	of	all	ten	mammary	glands	of	the	animal.	Image	
was	adapted	from	Sue	Knoblaugh,	Julie	Randolph-Habecker	
Steve	Rath,	in	Comparative	Anatomy	and	Histology,	2012. 
2.5	Animal	Surgery	
For	the	surgical	procedures,	animals	were	maintained	under	constant	anesthesia	by	
isoflurane	 inhalation	 (1.5-3%	 in	 0.8	 L/min,	 Abbott)	 using	 a	 Non-Rebreathing	
anesthesia	machine.	Ophthalmic	 ointment	was	 applied	 to	 the	 eyes	 of	 the	mice	 to	
prevent	 drying.	 Surgical	 tools	 were	 autoclaved	 and	 then	 disinfected	 with	 70%	
ethanol	prior	to	procedures.	The	fur	from	the	site	of	surgery	was	removed	by	local	
application	of	hair	removal	cream	(Veet),	following	which	the	area	was	cleaned	with	
1x	PBS.	A	small	 incision	 in	the	naked	skin	was	made	using	a	10cm	scissors	and	the	
mammary	gland	was	carefully	separated	from	the	skin	and	subcutaneous	layer	using	
a	 forceps	prior	 to	excision	with	the	scissors.	The	 incision	area	was	disinfected	with	
betadine	solution	and	it	was	closed	using	wound	clips,	animals	were	transferred	to	a	
clean	 cage	placed	under	a	heating	pad	 to	allow	 recovery	after	 the	procedure.	 The	
tissue	sample	was	 then	collected	 for	histology	 in	10%	neutral	buffered	 formalin	or	
snap	frozen	in	liquid	nitrogen	for	RNA	extraction.		
2.6	Extraction	of	MEFs	
Following	the	setting	up	of	the	breeding,	the	female	mouse	was	monitored	regularly	
for	 the	 vaginal	 plug	 and	 the	 exact	 date	 of	 which	 was	 noted.	 The	 mouse	 was	
sacrificed	12.5	–	13.5	days	after	 the	confirmation	of	vaginal	plug	and	 the	embryos	
were	collected	in	sterile	1x	PBS.	All	further	work	was	carried	out	in	sterile	conditions	
under	a	 laminar	flow	cabinet.	Embryos	were	carefully	separated	from	the	amniotic	
sac	with	a	pair	of	tweezers,	 following	which	the	head	was	removed	for	genotyping	
and	the	liver	was	separated	from	the	rest	of	the	body.	This	portion	of	the	body	was	
then	digested	overnight	 at	 4°C	with	500µl	 of	 0.05%	 trypsin	 following	which	 it	was	
mechanically	disassociated	with	a	pipette	and	plated	in	a	150mm	cell	culture	dish	for	
further	in	vitro	work.	
R1	 L1	
L2/3	R2/3	
R4	 L4	
R5	 L5	
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2.7	Genotyping	
Mice	were	weaned	3	weeks	after	birth	and	a	small	piece	of	the	tail	 is	removed	for	
genotyping.	DNA	was	extracted	from	mouse	tail	by	incubation	in	200µL	0.05M	NaOH	
at	98ºC	for	1.5h	and	subsequent	neutralization	with	20µL	1M	Tris	HCl	ph7.5.	For	the	
genotyping	of	the	MEFs,	the	heads	of	the	embryos	were	digested	with	400µL	0.05M	
NaOH	at	98ºC	for	1.5h	followed	by	neutralization	with	40µL	1M	Tris	HCl	ph7.5.	Each	
PCR	reaction	consisted	of	1µl	of	extracted	tail	DNA	and	20µl	PCR	mastermix	which	
was	composed	of:	Dream	Taq	Green	Buffer	 (Thermo	Scientific)	1X,	200	µM	dNTPs,	
Taq	Polimerase	1U/20µl,	0.25pmol/µl	FW	primer,	0.25	pmol/µl	RW	primer	and	dH2O.	
The	primers	utilized	for	the	different	transgenes	are	listed	below.	The	following	PCR	
program	was	applied	for	all	genes:		94°C	for	2	min,	30	times	[95°C	for	30	s,	60°C	for	
30	s,	72°C	for	30	s],	and	a	final	step	at	72°C	for	1	min.	
	
Table:	PCR	Primers	(Sigma)	
Gene	 Primer	Name	 Sequence	
TetO-Kras	
Kras4bfwd/DT12	 GGGAATAAGTGTGATTTGCCT	
Kras4brev/rev	mp1.2	 GCCTGCGACGGCGGCATCTGC	
ColA1-Plk1	
Primer	Coll	frt	A	 GCACAGCATTGCGGACATGC	
Primer	Coll	frt	B	 CCCTCCATGTGTGACCAAGG	
Primer	Coll	frt	C1	 GCAGAAGCGCGGCCGTCTGG	
Rosa26-rtTA	
Common	(HET)	 AAAGTCGCTCTGAGTTGTTAT	
Wild	type	Reverse	(WT)	 GGAGCGGGAGAAATGGATATG	
Mutant	Reverse	(MT)	 GCGAAG	AGT	TTG	TCC	TCAACC	
MMTV-rtTA	
CMV-rtTA	F	 GTGAAGTGGGTCCGCGTACAG	
CMV-rtTA	R	 GTACTCGTCAATTCCAAGGGCATCG	
TetO-Neu	
TAN-IRES	3528F	 GACTCTCTCTCCTGCGAAGAATGG	
TAN-IRES	3914B	 CCTCACATTGCCAAAAGACGG	
H2B-GFP	
H2B	EGFP	(F)	 CAAGGGCGAGGAGCTGTT	
H2B	EGFP	(R)	 AAGTCGTGCTGCTTCATGTG	
	
2.8	Immunohistochemistry	and	Immunofluorescence	of	Tissue	Sections	
The	samples	obtained	after	necropsy	 (Section	2.4)	were	embedded	 in	paraffin	and	
sectioned	 at	 3-5µm	 thickness	 using	 a	 rotary	microtome	 (Leica)	 on	 to	 a	 superfrost	
slide.	 Standard	 protocol	 using	 xylene	 and	 ethanol	 was	 used	 for	 deparaffinization.	
Antigen	retrieval	step	was	carried	out	with	0,09%	(v/v)	unmasking	solution	(Vector)	
for	40min	in	a	steamer,	the	slides	were	allowed	to	cool	down	to	room	temperature	
before	washing	with	 running	water.	 After	 antigen	 retrieval,	 the	 tissue	 sections	 on	
the	slides	were	encircled	with	a	PAP	pen	(Sigma)	and	3%	H2O2	(Sigma)	was	applied	
on	the	sections	to	inactivate	endogenous	peroxidases.	Species-specific	VECTASTAIN	
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Elite	 ABC	 kits	 (Vector)	 were	 used	 as	 per	 manufacturer	 guidelines	 for	 blocking,	
secondary	 antibody	 staining	 and	 biotin-streptavidin	 binding.	 Primary	 antibody	
incubation	durations	varied	depending	on	the	specific	antibody.	Peroxidase	reaction	
to	 detect	 primary	 antibody	 was	 carried	 out	 using	 DAB	 Peroxidase	 Substrate	 kit	
(Vector)	 and	 haematoxylin	 QS	 (Vector)	 was	 used	 for	 DNA	 counterstaining	 for	 the	
nuclei	 detection.	 Sections	 were	 dehydrated	 and	 mounted	 with	 DPX.	
Immunofluorescence	was	 performed	 after	 deparaffinization	 of	 paraffin	 embedded	
tissue	sections	as	described	above.	Permeabilization	of	 tissue	was	then	carried	out	
using	1x	PBS	with	0.2%	Triton	X100	for	10min,	blocking	was	achieved	using	5%	goat	
serum	 or	 donkey	 serum	 (Jackson	 Immuno)	 in	 PBS	 with	 0.15	 %	 Triton	 X100	 for	 a	
duration	of	1hr.	Primary	antibodies	were	diluted	in	blocking	solution	and	incubated	
overnight	at	4°C	or	2hrs	at	room	temperature.	Following	washes	with	1xPBS,	Alexa	
fluorophor	 labeled	 goat/donkey	 IgG	 (1:250,	 Invitrogen)	 secondary	 antibodies	were	
incubated	 for	 1hr	 at	 room	 temperature.	 DAPI	 (Life	 Technologies)	 was	 used	 for	
nuclear	 staining	 and	mounted	 with	 Prolong	 Antifade	mounting	media.	 Imaging	 of	
immunohistochemistry	sections	was	performed	using	Zen	blue	software	(Zeiss)	on	a	
Zeiss	Axioplan	microscope.	Slide	 scanning	was	carried	out	using	 the	Zeiss	Axioscan	
system	 or	 the	 TISSUEFAX	 (Tissuegnostics).	 Image	 analysis	 was	 done	 using	 Fiji	
(https://fiji.sc/)	 and	 Strataquest	 software	 (Tissuegnostics)	 for	 scanned	 sections.	
Primary	 antibodies	 used	 were	 against	 pH3	 Ser10	 (1:200,	 Cell	 Signaling,	 9701),	
Pericentrin	 (1:3000,	Abcam	ab4448),	 γ-H2aX	 (1:500,	Bethyl	 labs),	p21	 (1:50,	 Santa-
Cruz	 SC-6246),	 PCNA	 (1:8000,	Abcam	ab18197),	 Plk1-phospho	T210	 (1:500,	Abcam	
ab39068)	and	Plk1	(1:20,	(Trakala	et	al,	2015)).	TUNEL	(In	Situ	Cell	Death	Detection	
Kit,	TMR	red,	Roche,	#	12156792910)	was	used	for	detecting	cell	death.	
2.9	Interphase-FISH	
For	interphase-FISH,	formalin	fixed	tissue	was	processed	and	sectioned	as	described	
in	the	previous	section;	similarly	deparaffinization	with	xylene	and	rehydration	with	
graded	ethanol	was	carried	out.	Vysis	Paraffin	Pretreatment	IV	&	Post-Hybridization	
Wash	buffer	kit	was	used	as	specified	by	the	manufacturer.	Probe	mix	was	prepared	
with	3µl	of	labeled	probe	and	7µl	Vysis	LSI/WCP	Hybridization	buffer.	The	probe	mix	
was	spread	on	the	tissue	section	and	a	22x22mm	coverslip	 (Prestige)	was	carefully	
placed	on	the	section	and	sealed	with	Fixogum.	Hybridization	was	performed	using	
Thermobrite	 system	 (Abbott	Molecular)	with	 the	 following	 program:	Denaturation	
76ºC	for	5	min,	hybridization	at	37ºC	for	20-24	h.	The	pan-centromeric	probes	were	
made	using	pairs	of	BAC	clones	for	each	chromosome.	Chr	16-RP23-290E4	&	RP23-
356A24	 labeled	 with	 SpectrumOrange-dUTP	 (Vysis);	 and	 Chr	 17-RP23-354J18	 &	
RP23-202G20,	labeled	with	SpectrumGreen-dUTP	(Vysis);	the	BAC	DNA	were	labeled	
by	nick	 translation	according	 to	 standard	procedures.	 Imaging	was	done	using	Zen	
black	software	(Zeiss)	on	a	Zeiss	cell	observer	microscope.	Signal	for	hybridization	for	
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each	 probe	was	 checked	 in	 a	minimum	of	 60	 interphase	 cells,	 image	 analysis	was	
done	using	Fiji	(https://fiji.sc/).	
2.10	Whole	Genome	Sequencing	(Low	Coverage)	
Snap	 frozen	 tissue	was	used	 for	extraction	of	genomic	DNA	using	DNeasy	Blood	&	
Tissue	 Kit	 (Qiagen)	 as	 per	 manufacturer	 guidelines.	 For	 Library	 preparation,	 the	
Beckman	Biomek	 FX	 automated	 liquid	 handling	 system	was	 utilized.	 SPRIworks	HT	
chemistry	(Beckman	Coulter)	was	employed	to	provide	total	genomic	DNA	of	500ng	
as	 starting	 material.	 Quality	 control	 and	 library	 quantification	 was	 done	 with	 a	
Fragment	 Analyser	 (Advanced	 Analytics	 Technologies,	 Ames,	 USA).	 Illumina	 HiSeq	
2500	platform	(Illumina,	San	Diego,	USA)	was	used	for	next	generation	sequencing.	
The	 DKFZ	 Genomics	 and	 Proteomics	 core	 facility	 handled	 library	 preparation	 and	
sequencing.	For	the	analysis	of	the	sequencing	data,	the	reads	were	aligned	to	mm	
10	 build	 of	mouse	 reference	 genome	 using	 BWA.	 Tumor	 coverage	 files	were	 log2	
normalized	to	genomic	DNA	obtained	from	normal	mammary	mouse	tissue.	Circular	
binary	 segmentation	 (R	 package,	 CBS)	 was	 applied	 and	 somatic	 copy	 number	
alterations	 (SCNA)	 were	 manually	 characterized	 as	 detailed:	 whole	 chromosome	
gains/losses	 are	 chromosome	 wide	 shifts	 in	 the	 segmentation	 of	 a	 chromosome	
whereas	partial	 chromosome	gains/losses	 entail	 losses/gains	of	 at	 least	 1/5	of	 the	
chromosome.	 Focal	 amplifications	 and	 deletions	 encompass	 events	 smaller	 than	
this.	 Gross	 chromosomal	 rearrangements	 were	 called	 when	 the	 number	 of	 copy	
number	 state	 switches	 on	 a	 chromosome	 exceeded	 a	 total	 of	 10.	 The	 Korbel	
Laboratory	 (Genome	Biology,	 EMBL	Heidelberg)	was	 responsible	 for	 analysis	 of	 all	
next	generation	sequencing	data.		
	
2.11	Real-Time	Quantitative	PCR	
For	RNA	analysis,	snap	frozen	tissue	collected	as	described,	was	homogenized	using	
a	mortar	and	a	pestle	while	using	dry	ice	or	liquid	nitrogen	to	maintain	temperature	
below	 –80ºC.	 RNA	 extraction	 was	 carried	 out	 following	 manufacturer’s	
recommendations	 (RNeasy	Mini	 Kit,	 Qiagen).	 QuantiTect	 Reverse	 Transcription	 Kit	
(Qiagen)	was	used	for	cDNA	synthesis	utilizing	400ng	of	RNA,	measured	using	a	Nano	
Drop	 2000	 (Thermo	 Scientific).	 Quantification	 using	 Real-time	 PCR	 was	 initiated	
using	12ng	of	 cDNA	with	SYBR	Green	PCR	Master	Mix	 (2x)	 (Applied	Biosystems)	 in	
LightCycler	II®	480	(Roche).	Relative	gene	expression	was	calculated	as	depicted:	ΔCt	
=	 Ct	 (gene	 of	 interest)	 –	 Ct	 (housekeeping	 gene);	 ΔΔCt	 =	 ΔCt	 –	 ΔCt	 (reference	
sample);	Relative	Expression	=	2^(–ΔΔCt).	The	list	of	primers	is	as	follows:		
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Gene	 Forward	(5'-3')	 Reverse	(5'-3')	
Actin	B	 GCTTCTTTGCAGCTCCTTCGT	 ACCAGCCGCAGCGATATCG	
Plk1	 AACACGCCTCATCCTCTACAAT	 AGGAGGGTGATCTTCTTCATCA	
Her2	 TGTACCTTGGGACCAGCTCT	 GGAGCAGGGCCTGATGTGGGTT	
Kras	 AAGGACAAGGTGTACAGTTATGTGA	 CTCCGTCTGCGACATCTTC	
rtTA	 CGCGTTATATGCACTCAGCG	 TAAGAAGGCTGGCTCTGCAC	
In	vitro	Culture	Systems	
2.12	MEF	Culture	and	Live	Imaging	
Following	 the	 extraction	protocol	 detailed	 in	 section	 2.6,	 the	MEFs	were	 grown	 in	
Dulbecco’s	 modified	 Eagle	 medium	 (DMEM;	 Gibco)	 supplemented	 with	 2	 mM	
glutamine,	1%	penicillin/streptomycin	and	10%	tetracycline	free	foetal	bovine	serum	
(FBS;	biowest).	For	live	cell	imaging,	the	MEFs	were	plated	in	a	Poly-L-Lysine	coated	8	
well	slide	chambers	(ibidi).	Cultures	were	induced	using	1μg/ml	of	doxycycline	added	
to	 the	 culture	media	 6-8hrs	 prior	 to	 imaging.	 Treatment	with	 Nocodazole	 (Sigma)	
and	 Paclitaxel	 (Sigma)	 was	 carried	 out	 by	 adding	 1μM	 of	 the	 drug	 to	 the	 culture	
media	6hrs	before	imaging.	Time-lapse	imaging	was	performed	for	a	duration	of	12h	
using	 a	 Leica	 SP5	Confocal	microscope:	 2μm	optical	 sectioning	 across	 12μm	 stack,	
time-lapse	of	5	min.	
2.13	Chromosome	Spreads	
To	perform	chromosome	spreads,	MEFs	were	cultured	to	confluence	in	a	standard	6	
well	 culture	 plate	 and	 induced	 with	 1μg/ml	 of	 doxycycline	 added	 to	 the	 culture	
media.	 Cells	 were	 arrested	 by	 treating	 with	 1μM	 Nocodazole	 (Sigma)	 for	 6-8h	
followed	 by	 0.1μg/ml	 colcemid	 (Karyomax;	 ThermoFisher)	 for	 2h.	 MEFs	 were	
collected	 by	 trypsinization;	 cytoplasm	 swelling	 was	 achieved	 by	 75	 mM	 KCl	
treatment	for	15min	and	cells	were	fixed	with	fixative	(3:1	methanol/acetic	acid)	for	
20min.	 Fixed	 cells	 were	 splashed	 onto	 a	 superfrost	 slide	 placed	 in	 a	 humidified	
chamber	 to	 obtain	 chromosome	 spreads.	 The	 spreads	 were	 stained	 with	 Giemsa	
stain	(Sigma)	and	imaging	of	samples	was	carried	out	using	Zen	black	software	(Zeiss)	
on	a	Zeiss	cell	observer	microscope.	
2.14	Focus	Formation	Assay	
MEFs	 (1x106	 cells)	 were	 plated	 in	 a	 standard	 100mm	 culture	 dish	 and	 allowed	 to	
grow	for	24h	prior	to	transfection.	To	achieve	transformation,	cells	were	transfected	
with	plasmids	containing	HRas-V12	and	E1A	using	Calcium	Phosphate	transfection	kit	
(Sigma)	per	manufacturer	guidelines.	MEFs	were	induced	by	treatment	with	1μg/ml	
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of	doxycycline	added	to	the	culture	media.	The	cultures	were	monitored	regularly	to	
detect	the	formation	of	foci,	4	weeks	after	transfection	the	cells	were	fixed	using	7:1	
methanol/acetic	acid	and	stained	with	0.5%	crystal	violet	solution.	Following	washes	
with	 distilled	 water,	 the	 dishes	 were	 allowed	 to	 dry	 and	 the	 number	 of	 foci	 was	
counted.	
2.15	Immunofluorescence	and	Image	Analysis	
For	 immunofluorescence,	 MEFs	 were	 cultured	 on	 19mm	 coverslips	 (VWR)	 in	
standard	12	well	culture	plates	and	induced	with	1μg/ml	of	doxycycline	added	to	the	
culture	media.	 Cells	were	 fixed	using	pre-warmed	4%	PFA	 for	 7min	 at	 37°C	or	 1:1	
methanol-acetone	at	-20°C	followed	by	a	wash	with	1xPBS.	Permeabilization	of	fixed	
cells	was	 then	 carried	 out	 using	 PBS	with	 0.5%	 Triton	 X100	 for	 10min	 at	 37°C,	 all	
subsequent	 washes	 were	 done	 using	 PBS	 with	 0.15%	 Triton	 X100	 at	 room	
temperature.	 Blocking	 was	 carried	 out	 with	 10%	 goat	 serum	 or	 donkey	 serum	
(Jackson	 Immuno)	 in	 PBS	 with	 0.15	 %	 Triton	 X100	 for	 a	 duration	 of	 1hr.	 Primary	
antibodies	were	diluted	in	blocking	solution	and	incubated	overnight	at	4°C	or	2hrs	
at	 room	 temperature.	 After	 3	 washes	 for	 5	 min,	 secondary	 antibodies:	 Alexa	
fluorophore	 labeled	goat/donkey	 IgG	(1:250,	 Invitrogen)	 incubated	for	1hr	at	room	
temperature.	Coverslips	were	washed	3	times	again	before	they	were	mounted	on	a	
superfrost	 slide	 using	 Prolong	 Antifade	 mounting	 media	 with	 DAPI.	 Primary	
antibodies	 against:	 Plk1	 (1:2,	 (Trakala	 et	 al,	 2015)),	 Plk1-phospho	 T210	 (1:200,	
Abcam	 ab39068),	 Pericentrin	 (1:3000,	 Abcam	 ab4448),	 γ-Tubulin	 (1:1000,	 Sigma	
T6557),	Sgo1	(1:100,	S.	Taylor,	University	of	Manchester,	England,	UK),	CREST-Texas	
Red	conjugate	(1:500,	Antibody	 Inc),	α	tubulin	(1:500,	Sigma	T6199)	and	α	tubulin-
FITC	 conjugate	 (1:500,	 Sigma	 F2168)	were	 utilized.	 Leica	 TCS	 SP5	microscope	with	
Leica	LAS	4.5	software	was	used	for	imaging	and	image	analysis	was	done	using	Fiji	
(https://fiji.sc/).	 For	 the	 quantification	 of	 mean	 fluorescence	 intensity,	 all	 images	
were	converted	to	8-bit	grayscale	following	which	cell	borders	were	traced	using	the	
free	 hand	 tool	 in	 Fiji	 and	 mean	 pixel	 intensity	 for	 corresponding	 channel	 was	
calculated	within	the	defined	area.			
2.16	Western	Blotting	
For	protein	detection	by	 immunoblot,	MEFs	 cultured	 to	 confluence	 in	 standard	 six	
well	plates	were	collected	using	a	cell	scrapper.	Cells	were	then	lysed	using	RIPA	lysis	
buffer	(150mM	NaCl,	50mM	Tris	pH	8,	1%	Triton	X100,	0.5%	Sodium	deoxycholate,	
0.1%	 SDS)	 supplemented	 with	 PMSF	 (1:100)	 for	 15	 min	 on	 ice	 followed	 by	
centrifugation	at	4°C,	14000rpm	for	20	min.	Quantification	of	protein	was	done	using	
a	 spectrophotometer	and	Bradford	 reagent	 (Biorad).	Proteins	were	 first	denatured	
by	 boiling	 at	 100°C	 for	 10	min	 and	 run	 on	 a	 12%	 SDS	 poly-acrylamide	 gels	 (3.3ml	
dH2O,	 4ml	 30%	 acrylamide,	 2.5ml	 1.5M	 Tris	 pH	 8.8,	 100µl	 10%	 ammonium	
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persulfate,	 4µl	 TEMED)	 with	 stacking	 gel	 (1.45ml	 dH2O,	 335ml	 30%	 acrylamide,	
250µl	 1.5M	 Tris	 pH	 6.8,	 20µl	 10%	 ammonium	 persulfate,	 2µl	 TEMED)	 in	 running	
buffer	 (25mM	 Tris,	 250mM	 glycine,	 0.1%	 SDS)	 for	 several	 hours	 at	 120V.	
Nitrocellulose	 membrane	 of	 appropriate	 size	 was	 activated	 with	 methanol	 and	
soaked	in	transfer	buffer.	Proteins	were	transferred	onto	the	membrane	using	a	TE	
77	 PWR	 semi-dry	 transfer	 unit	 (Amersham	 Biosciences)	 at	 200mA	 for	 1.5hrs	
following	 manufacturer	 guidelines.	 Membranes	 were	 washed	 with	 1x	 TBS-T	 and	
blocking	was	done	using	5%	BSA	in	TBS-T	for	1hr.	Primary	antibodies	were	diluted	in	
blocking	 solution	 and	 incubated	 with	 the	 membrane,	 overnight	 at	 4°C.	 For	 the	
detection	 of	 the	 protein,	 horseradish	 peroxidase-linked	 species-specific	 secondary	
antibodies:	ECL	anti-rabbit	IgG	(1:10000,	NA934	Amersham)	and	ECL	anti-mouse	IgG	
(1:5000,	 NA931	 Amersham)	were	 used.	 The	 Blot	was	 revealed	 by	 incubation	with	
Amersham	ECL™	Prime	Western	Blotting	Detection	Reagent	 for	 3min,	 followed	by	
imaging	using	LAS	400	Image	Quant	(GE)	with	an	exposure	time	of	1-3min.	Primary	
antibodies	used	 for	western	blotting	were:	Actin	 (1:6000,	A2066	Sigma),	anti-FLAG	
(1:500,	2368s	Cell	Signaling)	and	anti-Plk1	(1:200,	4535s	Cell	Signaling).		
2.17	Organoid	Cultures	
All	10	mammary	glands	of	adult	female	mice	were	collected	as	described	in	section	
2.4.	 The	 tissue	 was	 then	 digested	 overnight	 (37°C)	 with	 20	 mg/ml	 Liberase	
Blendzyme	2	(Roche,	11988425001)	and	150	U/ml	Collagenase	type	3	(Worthington,	
no.	CLS3)	added	 to	DMEM	F-12	 (Lonza)	 supplemented	with	1%	Hepes	1M	 (Gibco),	
1%	 penicillin/streptomycin	 (Gibco).	 Tissue	 suspension	 was	 first	 mechanically	
disassociated	with	a	pipette,	followed	by	a	single	wash	with	sterile	1xPBS	and	further	
digestion	with	0.25%	trypsin	at	37°C	for	20	min.	Trypsin	was	deactivated	by	washing	
with	 DMEM	 F-12	 (Lonza)	 supplemented	 with	 2	 mM	 glutamine,	 1%	
penicillin/streptomycin	and	10%	tetracycline	free	FBS	(biowest).	The	cell	suspension	
was	 then	 treated	 with	 DNAseI,	 after	 which	 they	 were	 resuspended	 in	 Mammary	
Epithelial	 Growth	 Media	 (MEGM;	 Lonza)	 and	 cultured	 overnight	 in	 BioCoat™	
collagen	 coated	6well	 plates	 (Corning).	 This	 step	was	done	 to	enrich	 the	epithelial	
cell	population	 in	 the	culture.	The	cells	were	detached	and	collected	by	 treatment	
with	 0.25%	 trypsin	 at	 37°C	 for	 5min,	 the	 reaction	 was	 deactivated	 as	 described	
above	 and	 the	 cells	 were	 counted	 using	 an	 automated	 cell	 counter	 (Cellometer;	
Nexcelom	 Bioscience).	 A	 total	 of	 12,000	 cells	were	mixed	with	 90μl	 of	 3D	 culture	
matrix	 (Matrigel;	TEMA)	and	seeded	as	a	single	droplet	onto	Lab-Tek	 II	chambered	
glass	 slides	 and	 allowed	 to	 polymerize	 for	 20min	 at	 37°C.	 The	 cells	were	 cultured	
with	MEGM	 for	 6-8	 days	 till	 acini	 formation	 (Figure	 2.4)	 following	which	 they	 are	
induced	with	1mg/ml	of	doxycycline	added	to	the	culture	media.	Time-lapse	imaging	
of	organoid	cultures	was	performed	during	20h	on	an	inverted	spinning	disk	confocal	
(Perkin	 Elmer	 Ultraview-Vox):	 0.3μm	 optical	 sectioning	 across	 35μm	 stack,	 5	
frames/h	 and	 for	 a	 duration	 of	 12h	 using	 a	 Leica	 SP8	 Confocal	microscope	with	 a	
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resonant	scanner:	0.9μm	optical	sectioning	across	35μm	stack,	12	 frames/h.	 Image	
analysis	was	done	using	Fiji	(https://fiji.sc/).	
 
 
Figure	 2.4:	 Seeding	 of	 single	 murine	 mammary	 epithelial	 cells	 in	 matrigel	 and	 development	 of	
organoids	after	6-8	days	in	culture	
2.18	Immunofluorescence	of	Organoid	Cultures	
For	 immunofluorescence	 of	 organoid	 cultures,	 it	 was	 first	 necessary	 to	 partially	
predigest	 the	matrigel	using	150	U/ml	Collagenase	 type	3	 (Worthington,	no.	CLS3)	
and	20	mg/ml	Liberase	Blendzyme	2	(Roche,	no.	11988425001)	added	directly	to	the	
culture	 medium.	 Predigestion	 was	 carried	 out	 for	 the	 duration	 of	 45min	 at	 37°C,	
followed	by	washing	thrice	with	1xPBS	before	fixation	using	4%	PFA	for	5min	at	RT.	
Cultures	were	 then	washed	with	 1x	 IF	wash	 buffer	 (130	mM	NaCl	 (Sigma),	 7	mM	
Na2HPO4	 (Sigma),	 3.5	 mM	 NaH2PO	 (Sigma),	 7.7	 mM	 NaN3	 (Merck),	 0.1	 %	 BSA	
(Sigma),	0.2	%	Triton-X	(Sigma),	0.05	%	Tween	(Sigma),	pH	7.4.),	which	was	also	used	
for	all	subsequent	washes.	Blocking	was	carried	out	for	1,5hrs	using	10%	goat	serum		
(Jackson	ImmunoResearch)	and	1%	AffiniPure	F(ab')2	Fragment	Goat	Anti-Mouse	IgG	
(Jackson	ImmunoResearch)	in	1x	IF	wash	buffer.	Primary	antibodies	were	diluted	in	
blocking	solution	and	incubated	overnight	at	4°C.	Cultures	were	washed	3	times	for	
30	 min	 and	 incubated	 with	 Alexa	 fluorophor	 labeled	 goat/donkey	 IgG	 (1:800,	
Invitrogen)	secondary	antibodies.	This	was	followed	by	3	further	washes	for	30	min	
with	 1x	 IF	wash	buffer	 and	DAPI	 (1:2000).	 Cultures	were	 then	mounted	with	 anti-
fade	 agent	 Vectashield	 with	 Dapi	 (Vector	 laboratories).	 The	 primary	 antibodies	
utilized	 are:	 anti-Plk1-phospho	 T210	 (1:200,	 Abcam	 ab39068)	 and	 anti-Pericentrin	
(1:3000,	Abcam	ab4448).	Leica	TCS	SP5	microscope	with	Leica	LAS	4.5	software	was	
used	for	imaging	and	image	analysis	was	done	using	Fiji	(https://fiji.sc/).	
2.19	Statistical	analysis	
GraphPad	Prism	6	was	utilized	 for	all	 statistical	 testing.	Control	 samples	 for	 in	vivo	
experiments	were	obtained	 from	animals	 containing	 the	 transgenes	but	 kept	on	 a	
normal	diet	or	animals	lacking	MMTV-rtTA	but	placed	under	a	doxycycline	enriched	
diet.	Non-induced	cultures	(–Dox)	were	considered	as	controls	in	vitro.	
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Results	
The	Effect	of	Plk1	Overexpression	on	Tumorigenesis		
3.1	Plk1	does	not	function	as	an	oncogene	in	vivo	
The	oncogenic	potential	of	Plk1	has	been	widely	debated	over	the	past	two	decades.	
To	finally	put	this	debate	to	rest,	our	collaborators	at	the	Malumbres	laboratory	(Cell	
Division	 and	 Cancer	 Group,	 CNIO)	 developed	 an	 inducible	 mouse	model	 in	 which	
FLAG	 tagged	 human	 Plk1	 is	 expressed	 under	 the	 Tet-inducible	 ubiquitous	 Rosa26	
promoter	 (Section	 2.1).	When	 these	mice	were	 switched	 to	 a	 diet	 of	 food	 pellets	
with	doxycycline	(tetracycline	analog)	to	induce	transgene	expression,	they	showed	
no	significant	difference	in	tumor	free	survival	or	percentage	of	spontaneous	tumor	
incidence	in	comparison	to	the	control	group	(Fig	3.1a,	b).	The	mice	lacking	the	Plk1	
transgene	 (+/+);(+/rtTA)	 served	 as	 controls	 and	 the	 animals	 heterozygous	 for	 Plk1	
and	 Rosa26-rtTA	 (+/Plk1)(+/rtTA)	 formed	 the	 experimental	 group.	 These	 results	
suggested	 that	 Plk1	 when	 overexpressed	 in	 vivo	 lacked	 any	 oncogenic	 potential.	
Guillermo	 de	 Cárcer	 from	 the	 Malumbres	 laboratory	 carried	 out	 the	 initial	
characterization	of	the	Plk1	mouse	model.	
	
 
 
Figure	3.1:	a)	Tumor-free	survival	of	(+/+)	;(+/rtTA)	and	(+/Plk1)(+/rtTA)	mice	fed	with	Dox	since	birth	
during	85	weeks.	 (+/+)(+/rtTA),	19	mice;	 (+/Plk1)(+/rtTA),	24	mice.	p=0.2836;	Log-rank	 (Mantel-Cox)	
Test.	 b)	 Percentage	 of	 mice	 with	 spontaneous	 tumors.	 (+/+)(+/rtTA),	 19	 mice;	 (+/Plk1)(+/rtTA),	 24	
mice.	p=0.1247;	(Data	courtesy	of	Malumbres	laboratory,	CNIO,	Spain).	
3.2	Overexpression	of	Plk1	delays	mammary	tumor	initiation	in	Kras	and	or	Her2	
driven	breast	cancer	models.	
For	studying	the	effect	of	elevated	levels	of	Plk1	during	mammary	tumorigenesis,	we	
generated	new	mouse	models	by	crossing	mice	containing	the	tetracycline	inducible	
Plk1	with	mice	of	Kras/Her2	oncogenic	background,	in	which	the	mammary	specific	
MMTV-rtTA	promoter	controls	 the	gene	expression	 (Section	2.1).	The	progenies	of	
these	crosses	were	used	for	this	study.	Female	transgenic	mice	above	the	age	of	8	
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weeks	were	put	on	a	doxycycline	diet	to	switch-on	the	expression	of	the	transgenes	
present.	
Plk1	overexpression	on	its	own	did	not	display	any	oncogenic	potential	and	behaved	
similar	 to	 the	 control	 cohort;	 these	 findings	 were	 in	 line	 with	 the	 data	 from	 the	
Malumbres	 laboratory	 for	 the	ubiquitous	overexpression	of	Plk1,	described	earlier.	
In	 combination	 with	 the	 oncogenes	 KrasG12D	 or	 Her2,	 it	 was	 observed	 that	 Plk1	
played	 a	 tumor	 suppressive	 role	 by	 significantly	 delaying	 tumor	 initiation.	 The	
overexpression	 of	 the	 oncogene	 KrasG12D	 yielded	 mammary	 tumors	 in	 mice	 at	
around	172	days,	whereas	KrasG12D/Plk1	animals	took	significantly	longer	to	develop	
tumors	 and	 tumor	 development	was	 completely	 suppressed	 in	 90%	 of	 the	 colony	
(Figure	3.2a).	 In	 the	Her2	mice	 the	 first	palpable	 tumors	were	observed	at	around	
112	 days	 after	 doxycycline	 induction,	 in	 comparison	 Her2/Plk1	 animals	 developed	
tumors	 much	 later	 around	 349	 days	 following	 induction	 and	 in	 addition	 Plk1	
overexpression	 also	 completely	 prevented	 tumor	development	 in	 52%	of	 the	 total	
colony	(Figure	3.2b).	It	must	be	noted	that	mice	have	10	mammary	glands;	each	of	
them	can	potentially	develop	tumors,	however	elevated	levels	of	Plk1	also	reduced	
number	of	mammary	glands	that	underwent	transformation	(Figure	3.2c).		
	
 
 
  
 
Figure	 3.2:	 a)	 Percentage	 of	 tumor-free	 animals	 after	
doxycycline	 administration;	 (Control,	 n=33,	 Plk1/MMTV-
rtTA	n=35,	KrasG12D	n=20,	KrasG12D/Plk1	n=39).	Mantel-Cox	
test,	 p<0.0001.	 b)	 Tumor-free	 survival	 percentage	 after	
doxycycline	 administration;	 (Control	 n=33,	 Her2	 n=13,	
Her2/Plk1	 n=36).	 Mantel-Cox	 test,	 p<0.0001.	 c)	 Tumors	
per	 animal;	 **,	 p<0.01;	 ****,	 p<0.0001	 Mann-Whitney	
test.	
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3.3	Consequence	of	Plk1	overexpression	on	tumor	progression	
Histological	 analysis	 of	 the	 mammary	 tumors	 revealed	 that	 those	 tumors	 with	
elevated	 Plk1	 levels	 clearly	 displayed	 an	 increase	 in	 the	 frequency	 of	 polyploidy,	
denoted	by	cells	with	increased	nuclear	volume.	Figure	3.3	clearly	depicts	that	there	
is	a	 significantly	higher	percentage	of	 these	cells	with	 increased	nuclear	volume	 in	
tumors	with	Plk1	overexpression	when	compared	to	normal	mammary	gland	control	
as	well	as	single	oncogene	tumors.	Increased	nuclear	volume	is	a	phenotype	usually	
associated	 with	 higher	 total	 genomic	 content	 resulting	 from	 polyploidy.	 Genome	
doubling	events	leading	to	polyploidy	have	been	proposed	to	be	early	stage	events	
leading	 to	 tumor	 initiation	 (Kirkland,	 1966).	 The	 timing	 and	 exact	 mechanism	 by	
which	elevated	Plk1	results	in	tetraploidization	will	be	a	topic	of	discussion	later.	
	
      
 
Figure	 3.3:	 Immunohistochemistry	 against	 Plk1	 in	 paraffin	 sections	 of	mammary	 tumors.	 Scale	 bar	
20μm.	Graph	depicts	quantification	of	nuclear	volume	of	tumors	relative	to	control	cells	at	100days	
on	 doxycycline	 (CTRL:	 n=30;	 Kras:	 n=30;	 Kras/Plk1:	 n=40;	 Her2:	 n=46;	 Her2/Plk1:	 n=45);	 points	
represent	single	nuclear	measurements;	Kruskal-Wallis	 test,	Dunn’s	multiple	comparisons	 test.	*p	<	
0.05,	**p	<	0.01.	Number	of	animals:	(CTRL:	3;	Kras:	4;	Kras/Plk1:	4;	Her2:	5;	Her2/Plk1:	5).		
3.4	Genome	doubling	caused	by	elevated	Plk1	promotes	the	tolerance	of	
aneuploidy	
Polyploid	cells	are	a	common	occurrence	in	several	solid	tumors	and	recent	studies	
support	the	hypothesis	 that	these	cells	 resulting	 from	genome-doubling	events	are	
an	intermediary	step	to	aneuploidy	in	tumors	(Davoli,	de	Lange	and	Lange,	2011).	To	
validate	if	this	holds	true	in	our	genetically	engineered	mouse	models,	we	utilized	I-
FISH	to	verify	the	frequency	of	aneuploidy	in	the	different	tumor	models	described	
earlier.	 Results	 indicated	 that	 the	 tumors	 that	 harbored	 a	 higher	 percentage	 of	
polyploid	cells	also	showed	the	highest	frequency	of	aneuploidy	(Figure	3.4).	In	this	
case	 Plk1	 overexpression	 in	 the	 tumors	 correlates	 with	 increased	 tolerance	 of	
aneuploidy.	 This	 is	 in	 line	with	 recent	 findings	 demonstrating	 that	 whole	 genome	
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doubling	promotes	 chromosomal	 instability	which	 causes	 aneuploidy	 (Dewhurst	et	
al.,	 2014).	 Chromosomes	 16	 and	 17	 were	 counted	 and	 cells	 were	 considered	
aneuploid	 if	 they	 housed	more	 than	 the	 usual	 diploid	 (2n)	 chromosome	 count	 for	
either.	 Tetraploid	 cells	 were	 identified	 as	 those	 that	 harbored	 4n	 or	 more	
chromosomes.	
	
        
 
Figure	 3.4:	 Interphase-Fluorescent	 in	 situ	 hybridization	 (I-FISH)	 on	 paraffin	 sections	 of	 mammary	
tumors	 using	 two	 centromeric	 probes	 against	 chromosomes	 16	 and	 17.	 Histograms	 display	
quantification	 of	 the	 frequency	 of	 aneuploidy	 (top)	 and	 tetraploidy	 (bottom)	 in	 samples	 from	 the	
indicated	 genotypes	 (Control,	 n=4;	 Kras,	 n=4;	 Kras/Plk1,	 n=3;	 Her2,	 n=4;	 Her2/Plk1,	 n=4	 mice).	 *,	
p<0.05;	***,	p<0.001;	One-way	ANOVA.	
	
The	 results	 from	 the	 I-FISH	were	 supplemented	 by	 the	 data	 obtained	 from	whole	
genome	sequencing	(WGS)	of	the	Her2	and	Her2/Plk1	tumors,	the	Kras/Plk1	tumors	
were	not	sequenced	due	to	lack	of	material.	This	method	of	low	coverage	WGS	can	
be	used	to	detect	any	chromosomal	aberrations	that	are	present	in	a	majority	(60%	
or	more)	of	 the	cells	 from	a	 tumor.	WGS	 is	 limited	 in	 terms	of	histological	context	
and	single	cell	level	resolution	demonstrated	by	I-FISH,	however	it	makes	up	for	that	
by	 contributing	 precise	 structural	 resolution	 for	 the	 entire	 genome.	 A	 total	 of	 10	
Her2	 tumors	 and	 9	 Her2/Plk1	 tumors	 were	 sequenced	 and	 somatic	 copy	 number	
alterations	(SCNAs)	per	tumor	were	analyzed.	The	SCNAs	were	divided	into	separate	
categories	 as	 follows:	 	 whole	 chromosome	 gain	 (WCG)	 and	 loss	 (WCL),	 partial	
chromosome	 gain	 (PCG)	 and	 loss	 (PCG),	 focal	 amplification	 (AMP),	 focal	 deletion	
(DEL)	and	gross	chromosomal	rearrangements	(GCR)	(Figure	3.5a).	Overall,	the	Her2	
tumors	displayed	an	average	of	2.3	SCNA	compared	to	the	Her2/Plk1	tumors	with	an	
average	of	4	SCNAs	per	tumor	(Figure	3.5b).	The	Her2/Plk1	tumors	presented	with	
AMP,	frequent	DEL	and	GCR,	which	were	completely	absent	in	Her2	tumors	(Figure	
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3.5a).	 Analysis	 of	 the	 sequencing	 data	 was	 carried	 out	 by	 Christopher	 Buccitelli,	
Korbel	Group,	EMBL	Heidelberg.	
 
 
Figure	3.5:	a)	SCNAs	in	10	Her2	and	9	Her2/Plk1	tumors.	SCNAs	categorized	as	WCG,	WCL,	PCG,	PCL,	
AMP,	DEL	and	GCR.	b)	Average	SCNAs	in	primary	tumors	(Her2:	n=10;	Her2/Plk1:	n=9);	Mann-Whitney	
test.	*,	p	<	0.01.	Data	analysis	performed	by	Christopher	Buccitelli,	Korbel	Group,	EMBL	Heidelberg.	
3.5	Tumors	over	expressing	Plk1	proliferate	less	and	have	more	G1	arrested	cells	
A	 common	 consequence	 of	 polyploidy	 is	 the	 activation	 of	 p21	 through	 p53	
dependent	mechanism	resulting	 in	cell	 cycle	arrest	 (Ganem	and	Pellman,	2007).	 In	
agreement	with	the	literature,	immunohistochemistry	staining	of	p21	revealed	that	
the	tumors	with	elevated	Plk1,	which	possessed	higher	percentage	of	polyploid	cells,	
also	 displayed	 more	 p21	 positive	 cells	 (Figure	 3.6a).	 The	 percentage	 of	 cells	 that	
were	 still	 proliferating	 in	 these	 tumors	 was	 determined	 by	 PCNA	 staining	 and	 as	
expected,	 the	 results	 were	 reversed,	 the	 tumors	 with	 elevated	 Plk1	 displayed	 an	
overall	 lower	 proliferation	 than	 the	 single	 oncogene	 tumors	 (Figure	 3.6b).	 The	
tumors	overexpressing	Plk1	had	 lower	proliferation	rates	and	higher	percentage	of	
G1	arrested	cells	as	indicated	by	the	p21	staining.	
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Figure	 3.6:	 a)	 Immunohistochemistry	 against	 p21	 in	 paraffin	 sections	 of	 mammary	 tumors	 and	
quantification	 of	 percentage	 of	 positive	 cells	 per	 field	 of	 view	 (FOV	 per	 genotype	 -	 Kras:	 n=30;	
Kras/Plk1:	n=33;	Her2:	n=40;	Her2/Plk1:	n=45);	points	represent	percentage	of	positive	cells	per	FOV;	
Ordinary	 one-way	 ANOVA.	 **p	 <	 0.01,	 ****p	 <	 0.0001.	 Number	 of	 animals:	 (Kras:	 3;	 Kras/Plk1:	 3;	
Her2:	 4;	 Her2/Plk1:	 4).	 b)	 Immunohistochemistry	 against	 PCNA	 in	 paraffin	 sections	 of	 mammary	
tumors	and	quantification	of	percentage	of	positive	cells	per	field	of	view	(FOV	per	genotype	-	Kras:	
n=30;	Kras/Plk1:	n=30;	Her2:	n=36;	Her2/Plk1:	n=29);	points	represent	percentage	of	positive	cells	per	
FOV;	 Ordinary	 one-way	 ANOVA.	 **p	 <	 0.01,	 *p	 <	 0.05.	 Number	 of	 animals:	 (Kras:	 3;	 Kras/Plk1:	 3;	
Her2:	3;	Her2/Plk1:	3).	
Monitoring	early	stage	events	prior	to	tumor	initiation	
3.6	Plk1	overexpression	in	mammary	glands	prior	to	tumor	initiation	
Prior	 to	 studying	 the	 effects	 of	 Plk1	 over	 expression	 in	 tumors	 from	 these	mouse	
models,	 it	 was	 initially	 necessary	 to	 confirm	 the	 levels	 of	 expression	 of	 the	
transgene,	 as	 well	 as	 validate	 if	 the	 model	 depicted	 the	 human	 scenario	 as	
accurately	as	possible.	To	achieve	these	goals,	we	performed	immunohistochemistry	
against	Plk1	in	mammary	glands	obtained	from	the	models	described	in	section	3.2.	
The	mammary	glands	were	collected	at	4	days	and	100	days	after	the	administration	
of	doxycycline,	to	study	expression	levels	as	well	as	gradual	changes	in	morphology	
of	the	organ	prior	to	transformation.	All	mammary	glands	were	surgically	removed	
at	the	pro-estrous	phase	to	control	for	changes	induced	by	hormonal	fluctuations	as	
described	(Section	2.3,	2.4).		
Observations	 revealed	 that,	 Plk1	 expression	 was	 stable	 over	 time	 in	 the	 relevant	
transgenic	models	and	it	was	absent	in	the	age-matched	controls.	We	also	confirmed	
that	the	tumors	from	these	mice	continued	to	over	express	Plk1	and	the	expression	
was	 not	 completely	 lost	 because	 of	 malignant	 transformation,	 despite	 the	 strong	
tumor	 suppressive	 effects	 demonstrated	 in	 section	 3.2.	 In	 addition,	 we	 observed	
that,	 while	 mammary	 glands	 from	 the	 Kras	 and	 Her2	 animals	 showed	 signs	 of	
neoplastic	 growth	 at	 100days,	 the	 animals	 that	 had	 Plk1	 over	 expression	 had	
relatively	normal	mammary	gland	morphology	(Figure	3.7).		
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Figure	3.7:	Immunohistochemistry	against	Plk1	in	paraffin	sections	of	tumors	plus	mammary	glands	4	
days	and	100	days	on	doxycycline.	Scale	bar	50μm.	
Analysis	of	the	levels	of	the	transgenic	Plk1	using	RT-qPCR	(Figure	3.8a)	showed	that	
the	 average	 level	 of	 gene	 expression	 in	 the	 different	 models	 did	 not	 exceed	 the	
range	of	Plk1	expression	observed	 in	human	breast	cancer	cell	 lines	as	depicted	 in	
Figure	3.8b.	
 
 
 
 
Figure	3.8:	a)	RT-qPCR	showing	relative	expression	of	transgenic	Plk1	in	mammary	glands	4	days	and	
100	days	on	doxycycline.	b)	Gene	expression	of	Plk1	in	51	different	breast	cancer	cell	 lines	(Neve	et	
al.,	2009).	
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3.7	Increase	in	genomic	content	and	centrosome	number	as	a	consequence	of	Plk1	
overexpression	occurs	at	a	very	early	stage	
As	 discussed	 previously,	 elevated	 levels	 of	 Plk1	 resulted	 in	 a	 higher	 percentage	 of	
polyploidy	in	the	mammary	tumors.	To	better	determine	the	timing	of	the	genome-
doubling	 event,	 we	 performed	 histological	 analysis	 of	 mammary	 glands	 prior	 to	
tumor	development	and	measured	the	nuclear	volume	of	cells	over	expressing	Plk1,	
per	mammary	acini.	Surprisingly	there	was	an	increase	in	overall	nuclear	volume	as	
early	 as	 4	 days	 following	 induction	of	 Plk1	overexpression	 (Figure	 3.9a),	 indicating	
the	effect	of	Plk1	on	genome	doubling	of	cells	was	an	early	event.	The	 increase	 in	
percentage	 of	 polyploidy	 was	 also	 accompanied	 with	 a	 significantly	 higher	
percentage	of	 cells	 per	mammary	acini	with	3	or	more	 centrosomes	 (Figure	3.9b).	
Supernumerary	 centrosomes	 are	 a	 common	 consequence	 of	 tetraploidization	
(Meraldi,	Honda	and	Nigg,	2002).	
     
 
       
 
Figure	 3.9:	 a)	 Immunohistochemistry	 against	 Plk1	 in	 paraffin	 sections	 of	 mammary	 glands	 and	
quantification	 of	Nuclear	 volume	 relative	 to	 control	 cells	 at	 4days	 on	 doxycycline	 (Ctrl:	 n=30;	 Plk1:	
n=62)	 **p	 <	 0.01;	Mann-Whitney	 Test.	 Points	 represent	 single	 nuclear	measurements.	 Number	 of	
animals:	 (Ctrl:	 3;	 Plk1:	 6);	 Scale	 bar	 20μm.	 b)	 Immunofluorescence	 against	 pericentrin	 in	 paraffin	
sections	 of	 mammary	 glands	 and	 quantification	 of	 percentage	 of	 cells	 per	 acini	 with	 1,2	 or	 3	
centrosomes	at	 4days	on	doxycycline	 (Ctrl:	 n=170;	 Plk1:	 n=352)	 ***p	<	0.001;	Mann-Whitney	Test.	
Number	of	animals:	(Ctrl:	3;	Plk1:	3);	Scale	bar	20μm.	
3.8	Effect	of	Plk1	on	proliferation	and	cell	death	
Upon	confirming	that	Plk1	overexpression	led	to	tetraploidization	at	the	4-day	time	
point,	 it	was	essential	 to	determine	 if	 this	 inadvertently	 influenced	proliferation	or	
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cell	 death.	 Immunohistochemistry	 against	 Phospho-Histone3,	 which	 is	 commonly	
used	as	a	marker	of	proliferation	and	immunofluorescence	for	TUNEL	to	detect	the	
presence	of	apoptotic	cells	was	performed.	Although,	the	mammary	glands	with	Plk1	
over	expression	showed	an	overall	increase	in	the	percentage	of	pH3	positive	cells	in	
comparison	 to	 controls,	 there	 was	 no	 significant	 difference	 when	 compared	 to	
mammary	 glands	 from	 the	 Kras	 model.	 The	 results	 for	 the	 quantification	 of	 the	
percentage	of	TUNEL	positive	cells	revealed	a	similar	picture;	elevated	levels	of	Plk1	
significantly	 increased	 apoptosis	 with	 respect	 to	 the	 control	 mammary	 glands	
however	not	when	compared	to	single	oncogene	control.	Surprisingly	the	mammary	
glands	 from	 Kras/Plk1	 animals	 also	 showed	 an	 increase	 in	 percentage	 of	 pH3	 and	
TUNEL	positive	cells,	although	this	effect	was	not	compounded	(Figure	3.10a,	b).  
     
     
	
Figure	3.10:	a)	Immunohistochemistry	against	phospho-H3	in	paraffin	sections	of	mammary	glands	4	
days	on	doxycycline.	The	histogram	shows	the	percentage	of	pH3	positive	cells	per	acinus	(Ctrl:	n=42	
acini;	 Kras:	 n=42	 acini;	 Plk1:	 n=53	 acini;	 Kras/Plk1:	 n=58	 acini).	 Kruskal-Wallis	 test,	 Dunn’s	multiple	
comparisons	test.	***p	<	0.001,	****p	<	0.0001,	****p	<	0.0001.	Each	point	represents	single	acini	
and	 total	 quantification	 includes	 minimum	 6	 animals	 per	 genotype.	 b)	 Immunofluorescence	 using	
TUNEL	 kit	 in	 paraffin	 sections	 of	 mammary	 glands	 4	 days	 on	 doxycycline.	 The	 plot	 shows	 the	
quantification	of	percentage	of	TUNEL	positive	cells	per	acinus	(Ctrl:	n=51	acini;	Kras:	n=56	acini;	Plk1:	
n=28	acini;	Kras/Plk1:	n=24	acini)	Kruskal-Wallis	test,	Dunn’s	multiple	comparisons	test.	***p	<	0.001,	
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*p	<	0.05.	Each	point	represents	single	acini	and	total	quantification	includes	minimum	4	animals	per	
genotype.	
	
Thus,	 it	was	 possible	 to	 conclude	 Plk1	 overexpression	 influences	 proliferation	 and	
cell	death	in	the	mammary	gland,	however	this	is	not	significantly	different	from	the	
effects	caused	by	oncogene	induction.	
Mouse	Embryonic	Fibroblasts	(MEFs)	
3.9	Plk1	over	expression	leads	to	reduced	proliferation	and	increased	frequency	of	
mitotic	aberrations		
Earliest	studies	charactering	the	function	of	Plk1	showed	that	in	the	absence	of	this	
kinase,	 chromosomes	 failed	 to	orient	 in	 a	 proper	bi-polar	 spindle,	 instead	 forming	
mono	polar	spindles	 (Sunkel	and	Glover,	1988).	 It	was	also	observed	that	Plk1	had	
prominent	roles	in	controlling	the	timing	of	mitotic	entry	as	well	as	abscission	during	
cytokinesis.	 Considering	 the	 several	 functions	 of	 Plk1	 during	 cell	 division	 and	
furthermore	to	explain	the	phenotype	of	polyploidy	observed	in	vivo,	we	decided	to	
investigate	 the	effect	over	expressing	Plk1	has	on	mitotic	 cells	using	MEFs	derived	
from	the	Rosa26	ubiquitous	mouse	model	described	previously	(Section	3.1).	Unless	
specifically	 mentioned	 all	 experiments	 were	 carried	 out	 with	 heterozygous	
(+/Plk1)(+/rtTA)	 MEFs.	 The	 induction	 of	 the	 Plk1	 transgene	 was	 confirmed	 by	
performing	western	blot	 for	FLAG	tagged	Plk1	after	treatment	with	doxycycline	for	
12h	 (Figure	 3.11a).	 These	 initial	 observations	 were	 essential	 to	 confirm	 Plk1	
overexpression	in	MEFs	before	proceeding	to	more	elaborate	studies.	MEFs	provide	
an	 extremely	 versatile	 system	 to	 answer	mechanistic	 questions	 that	 can	 help	 the	
validation	of	in	vivo	phenotypes.		
Overexpression	 of	 Plk1	 in	 primary	 MEFs	 led	 to	 reduced	 proliferation	 in	 these	
cultures,	 monitored	 for	 5	 days	 post	 induction	 (Figure	 3.11b).	 Furthermore,	
immunofluorescence	of	MEFs	after	24h	of	induction	with	doxycycline	revealed	that	a	
significant	 number	 of	 cells	 with	 elevated	 Plk1	 displayed	 an	 array	 of	 mitotic	
aberrancies	as	represented	below	(Figure	3.11c).	The	mitotic	errors	were	categorized	
as	the	following:	monopolar	spindles,	multipolar	spindles,	lagging	chromosomes	and	
chromosome	bridges.	
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Figure	3.11:	a)	FLAG-Plk1	western	blot	of	protein	extracts	obtained	from	Plk1/Rosa26-rtTA	MEFs	(ON	
Dox:	 n=3	 replicates;	 OFF	 Dox:	 n=1	 replicate).	 b)	 Quantification	 of	 confluence	 in	 cultures	 in	 the	
absence	(–Dox)	or	presence	(+Dox)	of	Doxycycline	for	5	days.	**,	p<0.001	****,	p<0.0001;	Two-way	
ANOVA.	 c)	 Immunofluorescence	 against	 α-Tubulin	 and	 pericentrin	 in	 primary	 MEFs	 after	 24h	 on	
doxycycline	 induction	 followed	 by	 quantification	 of	 the	 percentage	 of	 mitotic	 aberrancies	 (–Dox:	
n=149	mitotic	cells;	+Dox:	n=166	mitotic	cells).	****,	p<0.0001;	2way	ANOVA.	
3.10	Plk1	suppresses	oncogenic	transformation	in	vitro	
The	results	from	section	3.2	indicated	that	Plk1	overexpression	strongly	suppressed	
KrasG12D	and	Her2	driven	mammary	tumorigenesis.	It	was	imperative	to	determine	if	
this	 was	 a	 tissue	 or	 oncogene	 specific	 effect,	 for	 this	 we	 analyzed	 if	 Plk1	
overexpression	could	suppress	in	vitro	transformation	of	primary	MEFs	by	oncogenic	
HrasV12	and	E1A.	Focus	 formation	assays	performed	using	Plk1/Rosa26-rtTA	MEFs	
transfected	with	oncogenic	HrasV12	+	E1A	revealed	that	when	Plk1	overexpression	
was	 induced	 by	 doxycycline	 there	 was	 a	 drastic	 reduction	 in	 the	 number	 of	
transformed	 foci	 (Figure	 3.12).	 These	 results	 suggested	 that	 Plk1	 overexpression	
could	suppress	oncogenic	transformation	in	vitro.	
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Figure	3.12:	Focus	formation	assays	of	Plk1/Rosa26-rtTA	MEFs	transfected	with	oncogenic	HrasV12	+	
E1A	 in	 the	 absence	 (–Dox)	 or	 presence	 (+Dox)	 of	 Doxycycline	 for	 4	 weeks.	 The	 number	 of	 foci	 is	
indicated	in	the	histogram.	*,	p<0.05	(n=2	replicates);	Unpaired	t	test.	
3.11	Plk1	increases	the	percentage	of	polyploidy		
It	 was	 essential	 to	 validate	 if	 the	 MEFs	 recapitulated	 the	 in	 vivo	 phenotype	
accurately.	To	check	if	the	MEFs	over	expressing	Plk1	were	polyploid,	flow	cytometry	
based	 analysis	 was	 performed	 by	 our	 collaborators	 at	 the	Malumbres	 laboratory.	
Total	 DNA	 content	 per	 cell	 after	 treatment	with	 doxycycline	 for	 24h	 and	 48h	was	
determined.	 In	 line	 with	 the	 in	 vivo	 data,	 the	 Plk1/Rosa26-rtTA	 MEFs	 showed	 a	
steady	 increase	 in	 the	 number	 of	 genome-doubled	 cells	 with	 increased	 time	 of	
doxycycline	treatment.	This	data	further	supports	that	Plk1	induces	polyploidy	by	a	
previously	unexplored	mechanism.	
	
 
 
Figure	 3.13:	 DNA	 content	 of	 Plk1/Rosa26-rtTA	 MEFs	 (homozygous	 for	 Plk1	 and	 Rosa26-rtTA),	
untreated	or	treated	with	Dox	for	24h	and	48h	respectively.	The	percentage	of	2N,	4N	or	8N	cells	is	
indicated	in	the	histograms	(Data	courtesy	of	Malumbres	laboratory,	CNIO,	Spain).		
3.12	Elucidating	the	mechanism	of	Plk1	induced	polyploidy	
The	 cumulative	 results	 showed	 an	 increase	 in	 polyploidy	 and	mitotic	 aberrations,	
indicating	 possible	 defects	 in	 mitotic	 progression.	 This	 hypothesis	 was	 verified	 by	
performing	time-lapse	 imaging	of	Plk1/Rosa26-rtTA/H2B-GFP	MEFs	after	 treatment	
with	doxycycline	for	the	duration	of	8h.	Images	were	captured	every	5	minutes	with	
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the	total	session	lasting	12h.	Fate	of	a	mitotic	cell	was	classified	based	on	observed	
phenotypes	 as:	 regular	 mitosis,	 cytokinesis	 failure,	 no	 segregation	 and	 mitotic	
regression.	
   
          
 
Figure	3.14:	a)	Time-lapse	microscopy	of	Plk1/Rosa26-rtTA	MEFs	off	Dox	(upper	panel)	and	after	8h	
on	doxycycline	(lower	panels),	indicating	mitotic	cells;	H2B-GFP	(green),	classified	based	on	the	three	
major	 phenotypes	 resulting	 in	 a	 tetraploid	 progeny	 in	 the	 case	 of	 Plk1	 overexpression.	 Scale	 bar	
20μm.	 b)	 Percentage	 of	 occurrence	 of	 each	 major	 phenotype	 in	 –Dox	 (n=141)	 and	 +Dox	 (n=164)	
MEFs.	 c)	 Percentage	 of	mitotic	 errors	 per	MEF	 (–Dox:	 141	 cells;	 +Dox:	 164	 cells);	 points	 represent	
individual	MEF	 line.	 ****,	 p<0.0001,	Unpaired	 T-test.	 d)	Duration	of	mitosis	 in	 the	MEF	 cultures	 (–
Dox:	141	cells;	+Dox:	164	cells).	****,	p<0.0001,	Unpaired	T-test.	
Results	indicated	a	significant	percentage	of	cells	(26.7%	versus	1.1%	in	control	cells)	
exited	 from	 mitosis	 prior	 to	 anaphase,	 without	 chromosome	 segregation.	 In	
addition,	38%	of	Plk1-overexpressing	cells	displayed	abnormal	 cytokinesis	 resulting	
in	 binucleated	 cells	 or	 underwent	mitotic	 regression	 thereby	 generating	 tetraploid	
cells	with	a	single	nucleus	(Figure	3.14a,	b)		
Timing	 in	 mitosis	 was	 calculated	 from	 the	 point	 of	 nuclear	 envelope	 breakdown	
(NEBD)	till	attachment;	it	was	also	interesting	to	note	that	the	MEFs	over	expressing	
Plk1	displayed	a	slight	increase	in	mitotic	timing	(Figure	3.14d).	This	experiment	was	
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clearly	able	to	demonstrate	that	Plk1	overexpression	resulted	in	genome	doubling	by	
mainly	two	independent	mechanisms,	either	due	to	complete	lack	of	segregation	or	
failure	at	cytokinesis.		
3.13	Activation	and	localization	of	Plk1	during	different	mitotic	phases	
Both	 the	 functions	 and	 the	 localization	 of	 Plk1	 during	 different	 phases	 of	 mitosis	
have	been	well	characterized	(De	Cárcer,	Manning	and	Malumbres,	2011).	Owing	to	
the	results	from	earlier	it	was	a	fair	assumption	that	the	elevated	levels	of	induced	
Plk1	 resulted	 in	 increased	activity	of	 the	kinase	during	mitosis.	We	verified	 this	by	
staining	doxycycline	treated	MEFs	with	an	antibody	that	recognizes	phosphorylation	
on	Thr210	at	the	Plk1	T-activation	loop.		
	
    
 
Figure	 3.15:	 Immunofluorescence	 against	 p-Plk1	 T210	 and	 pericentrin	 in	 primary	 Plk1/Rosa26-rtTA	
MEFs	after	24h	on	Dox.	The	histogram	shows	the	quantification	of	mean	fluorescence	intensity	(MFI)	
of	p-Plk1T210	staining	 in	 the	entire	cell	at	each	mitotic	phase	 (Prometaphase	 (PM):	–Dox	n=9	cells;	
+Dox:	n=11	 cells;	Metaphase	 (M):	 –Dox	n=10	 cells;	 +Dox:	n=7	 cells;	Anaphase	 (A):	 –Dox	n=11	 cells;	
+Dox:	 n=9	 cells;	 Cytokinesis	 (C):	 –Dox	 n=6	 cells;	 +Dox:	 n=6	 cells).	 ****,	 p<0.0001;	 *,	 p<0.05	 (n=3	
replicates);	1way	ANOVA	
The	quantification	of	the	signal	revealed	that	there	was	a	significant	increase	in	the	
accumulation	of	Plk1-pT210	at	prometaphase	and	metaphase	in	Plk1	over	expressing	
MEFs.	Although	the	other	phases	also	showed	a	trend	towards	 increased	activated	
Plk1,	 this	was	not	 found	to	be	significant	 (Figure	3.15).	 It	was	surprising	that	 there	
was	no	increase	in	Plk1	activity	during	cytokinesis;	especially	since	cytokinesis	failure	
was	 identified	as	one	of	the	major	mechanisms	that	resulted	 in	a	genome-doubled	
progeny.	It	can	be	theorized	that	the	cytokinesis	failure	was	due	to	an	effect	caused	
by	increased	Plk1	activity	in	one	of	the	earlier	phases.	However,	it	was	now	possible	
to	 associate	 the	 other	 major	 phenotype	 of	 lack	 of	 segregation,	 which	 resulted	 in	
mitotic	exit	prior	 to	anaphase	with	 the	 increase	 in	activated	Plk1	 in	prometaphase	
and	metaphase.	
To	explore	this	line	of	thought,	Plk1-pT210	signal	localized	at	individual	kinetochores	
during	 prometaphase	 was	 quantified.	 It	 was	 also	 necessary	 to	 show	 that	 Plk1	
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overexpression	using	this	doxycycline	inducible	system	did	not	affect	the	localization	
of	 the	protein	 at	 the	 kinetochores.	 For	 this	we	performed	 immunofluorescence	 to	
confirm	 co-localization	 of	 Plk1-pT210	 with	 a	 commonly	 used	 centromere	 marker,	
CREST	(Figure	3.16b).		
	
   
   
 
Figure	3.16:	a)	Immunofluorescence	against	p-Plk1T210	in	primary	Plk1/Rosa26-rtTA	MEFs	after	24h	
on	Dox.	The	histogram	shows	the	quantification	of	mean	fluorescence	intensity	(MFI)	of	p-Plk1	T210	
staining	 at	 individual	 kinetochores	 of	 cells	 in	 prometaphase	 (–Dox:	 n=51	 kinetochores;	 +Dox:	 n=51	
kinetochores)	**,	p	<	0.01	(n=2	cells);	Mann-Whitney	test.	b)	Immunofluorescence	against	p-Plk1T210	
and	CREST	in	primary	MEFs	after	24h	on	Dox.	
 
The	results	indicated	that	overexpression	of	Plk1	did	not	affect	its	localization	to	the	
kinetochore	 region	 and	 in	 line	 with	 the	 previous	 findings	 there	 was	 indeed	 an	
increase	in	localized	Plk1	activity	during	prometaphase	(Figure	3.16a).	
3.14	The	link	to	cohesion	and	the	loss	of	Sgo1	
The	 main	 function	 of	 Plk1	 from	 prometaphase	 till	 anaphase	 that	 was	 relevant	 in	
producing	the	phenotype	of	non-segregation	was	the	regulation	of	sister	chromatid	
cohesion.	 It	 has	 already	been	 shown	 that	one	of	 the	main	 targets	 of	 Plk1	prior	 to	
metaphase	is	Sgo1,	which	is	also	known	as	the	guardian	of	cohesion.	This	protein	is	
localized	at	the	centromeric	region	and	protects	cohesion	prior	to	separation.	When	
phosphorylated	 by	 Plk1	 at	 the	 end	 of	 metaphase,	 Sgo1	 is	 displaced	 from	 the	
kinetochores	and	cohesion	is	lost	(Kitajima	et	al.,	2006).	However,	we	theorized	that	
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with	the	overexpression	of	Plk1	it	is	probable	that	the	loss	of	cohesion	is	premature	
and	 cause	 the	 exit	 from	 mitosis	 without	 the	 occurrence	 of	 anaphase	 and	
chromosome	segregation,	resulting	in	a	tetraploid	progeny.	To	prove	this	hypothesis,	
we	 performed	 chromosome	 spreads	 of	 Plk1/Rosa26-rtTA	 MEFs	 treated	 with	
doxycycline	 for	 48h.	 The	 analysis	 of	 the	 results	 indicated	 that	 with	 doxycycline	
induction,	 there	 was	 an	 increase	 in	 the	 percentage	 of	 spreads	 containing	
chromosomes	with	partial	or	complete	 loss	of	cohesion	 indicated	by	the	separated	
arms	and	separated	sister	chromatids	respectively	(Figure	3.17).	
	
 
 
 
Figure	 3.17:	 Chromosome	 spreads	 from	 Plk1/Rosa26-rtTA	MEFs	 untreated	 or	 treated	with	 Dox	 for	
48h,	 where	 stained	with	 giemsa	 and	 evaluated	 under	 the	microscope.	 Chromosome	 cohesion	was	
classified	 in	 three	different	 status:	 “parallel	 arms”	as	 readout	of	 full	 chromatid	 cohesion	 (dark	blue	
box),	“separated	arms”	as	readout	of	chromatid	arm	separation	(mid	blue)	and	“separated	sisters”	as	
readout	 of	 fully	 separated	 chromatids	 (light	 blue).	 (–Dox	 n=35	 spreads;	 +Dox	 48h:	 n=27	 spreads).	
Scale	bar	20	μm.	
 
For	 verifying	wether	Plk1	overexpression	affected	 Sgo1	 localization,	we	performed	
immunofluroscence	 against	 Sgo1	 and	 quantified	 the	 signal	 in	 prometaphase	 cells	
after	24h	and	72h	of	doxycycline	treatment.		
	
The	observations	indicated	that	there	was	a	decrease	in	overall	Sgo1	staining	in	Plk1	
overexpressing	 MEFs.	 In	 concurrence	 with	 reduction	 of	 Sgo1	 there	 was	 also	 an	
increase	 in	the	percentage	of	cells	where	Sgo1	expression	was	diffused,	when	Plk1	
overxepression	was	 induced	 (Figure	3.18a).	We	also	 showed	 that	 Sgo1	 localization	
was	not	affected	in	the	controls	by	showing	co-localization	with	centromere	marker,	
CREST	(Figure	3.18b).	Taken	as	a	whole	this	provides	strong	evidence	 in	support	of	
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the	hypothesis	that	elevated	levels	of	Plk1	leads	to	lack	of	chromosome	segregation	
due	to	cohesion	loss.		
	
      
      
 
Figure	3.18:	a)	Immunofluorescence	against	p-Plk1	T210	and	Sgo1	in	primary	Plk1/Rosa26-rtTA	MEFs	
after	24h	and	72h	on	Dox.	The	first	histogram	shows	the	quantification	of	mean	fluorescence	intensity	
(MFI)	of	Sgo1	staining	in	the	entire	cell	at	prometaphase	(–Dox	n=34	cells;	+Dox	24h:	n=38	cells;	+Dox	
72h:	n=52	cells)	*,	p<0.01	(n=4	replicates);	***,	p<0.0001	(n=5	replicates);	1way	ANOVA.	The	second	
histogram	shows	the	percentage	of	prometaphase	cells	with	diffused	Sgo1	staining	(–Dox	n=34	cells;	
+Dox	24h:	n=38	cells;	+Dox	72h:	n=52	cells)	**,	p<0.001	(n=4	replicates);	**,	p<0.001	(n=5	replicates);	
1way	ANOVA.	b)	Immunofluorescence	against	Sgo1	and	CREST	in	primary	MEFs	after	72h	on	Dox.	
3.15	Secondary	effects	of	polyploidy:	extra	centrosomes	
Plk1	over	expression	 resulted	 in	 genome	doubled	progeny	as	evidenced	by	 results	
shown	earlier;	hence	it	was	worth	exploring	the	unavoidable	repercussions	this	has	
on	 subsequent	 mitotic	 divisions.	 One	 of	 the	 main	 consequences	 associated	 with	
tetraploidy	 resulting	 from	 a	 failed	 mitotic	 division	 is	 the	 presence	 of	 extra	
centrosomes	 (Meraldi,	 Honda	 and	 Nigg,	 2002).	 To	 explore	 this	 phenotype	 in	 Plk1	
overexpressing	 MEFs,	 cells	 were	 stained	 with	 the	 centrosome	 marker	 gamma-
tubulin	and	the	percentage	of	mitotic	cells	with	centrosomal	defects	was	analyzed.	
MEFs	with	Plk1	overexpression	showed	a	significant	increase	in	cells	with	abnormal	
centrosome	number,	mainly	attributed	to	supernumerary	centrosomes	(Figure	3.19).		
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Figure	3.19:	Immunofluorescence	against	Plk1	and	gamma-tubulin	in	primary	Plk1/Rosa26-rtTA	MEFs	
after	24h	on	Dox.	The	histograms	show	the	percentage	of	mitotic	cells	with	centrosome	abnormalities	
and	the	distribution	of	each	type	of	centrosome	defect.	 	 (Ctrl:	n=49	mitotic	cells;	Plk1:	n=61	mitotic	
cells)	**,	p	<	0.01	(n=2	replicates);	Mann-Whitney	test.	
 
Since	Plk1	also	plays	a	role	 in	centrosome	maturation	and	separation	(Wang	et	al.,	
2014),	we	needed	to	confirm	that	this	phenotype	was	not	caused	directly	by	induced	
Plk1	overexpression.	Centrosome	maturation	and	separation	happens	in	G1	and	late	
G2	phases	respectively.	To	find	out	 if	elevated	 levels	of	Plk1	affected	this	 function;	
We	 stained	 Plk1	 overexpressing	 MEFs	 with	 antibodies	 against	 Plk1-pT210	 and	
pericentrin	 a	 centrosome	marker	 and	 analyzed	 the	 staining	 intensity	 in	 interphase	
cells.	Results	 indicated	an	 increase	 in	the	amount	of	activated	Plk1	 localized	at	the	
separated	centrosomes	 in	G2	phase	however	there	was	no	significant	difference	 in	
the	 case	 of	 the	 joint	 centrosomes	 prior	 to	 that	 (Figure	 3.20).	 This	 may	 suggest	 a	
possible	effect	of	Plk1	overexpression	on	cells	prior	to	entry	into	mitosis.	
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Figure	 3.20:	 Immunofluorescence	 against	 p-Plk1	 T210	 and	 pericentrin	 in	 primary	 Plk1/Rosa26-rtTA	
MEFs	after	24h	on	Dox.	The	histogram	shows	the	quantification	of	mean	fluorescence	intensity	(MFI)	
of	 p-Plk1T210	 staining	 at	 the	 centrosomes	during	 late	G2	phase	 (separated)	 and	 rest	of	 interphase	
(joint)	(separated:	–Dox:	n=54	centrosomes;	+Dox:	n=34	centrosomes,	joint:	–Dox:	n=88	centrosomes;	
+Dox:	n=58	centrosomes)	**,	p<0.001	(n=2	replicates);	1way	ANOVA.	
Mammary	Organoids	
3.15	Mitotic	aberrations	and	tetraploidization	in	Plk1	overexpressing	mammary	
organoids	
The	 MEFs	 provided	 an	 elegant	 yet	 simple	 in	 vitro	 system	 to	 understand	 the	
underlying	mechanism	behind	the	tetraploidization	induced	by	Plk1	overexpression,	
however	 the	 aim	 of	 this	 study	 is	 to	 understand	 the	 consequences	 that	 elevated	
levels	of	Plk1	has	on	mammary	tumorigenesis.	If	we	were	to	extrapolate	the	results	
obtained	 by	 studying	 MEFs	 to	 mammary	 epithelial	 cells,	 we	 required	 an	
intermediate	in	vitro	system	of	study,	which	more	closely	resembles	our	GEMMs.	To	
address	this,	mammary	organotypic	cultures	were	directly	derived	from	Plk1/MMTV-
rtTA	mice	 as	 described	 previously	 by	 (Jechlinger,	 Podsypanina	 and	 Varmus,	 2009;	
Rowald	et	al.,	2016).	To	monitor	the	fate	of	epithelial	cells	after	induction	of	Plk1,	we	
performed	time-lapse	 imaging	of	spheroid	cultures	24h	post	 induction	of	Plk1	with	
doxycycline.	 Nuclear	 content	 was	 visualized	 by	 genetic	 expression	 of	 H2B-GFP;	
images	were	 captured	every	 5	minutes	with	 the	 total	 session	 lasting	 16h.	 Imaging	
time	had	to	be	limited	to	avoid	any	phototoxic	effect	to	the	cells.	
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Figure	 3.21:	 a)	 Time-lapse	 microscopy	 of	 Plk1/MMTV-rtTA	 mammary	 organoids	 untreated	 (upper	
panel)	and	after	24h	on	Dox	(lower	panel).	Yellow	circle	indicates	mitotic	cells;	H2B-GFP	(green).	Scale	
bar	 18	 μm.	 b)	 Duration	 of	 mitosis	 in	 the	 organoid	 cultures	 (–Dox:	 57	 cells;	 +Dox:	 43	 cells)	 ****,	
p<0.0001,	Unpaired	T-test.	c)	Percentage	of	mitotic	errors	per	mouse;	(–Dox:	57	cells	from	n=5	mice;	
+Dox:	 47	 cells	 from	 n=5	 mice).	 ****,	 p<0.0001,	 Unpaired	 T-test.	 d)	 Outcome	 of	 mitotic	 cells	
overexpressing	Plk1	after	36	hours.		
 
The	results	were	 in	congruence	with	the	experiment	conducted	using	MEFs	except	
for	a	few	exceptions.	Mammary	epithelial	cells	overexpressing	Plk1	also	resulted	in	a	
tetraploid	progeny	following	a	 failed	mitosis,	however	 in	 this	case	the	major	cause	
was	 lack	 of	 chromosome	 segregation	 followed	 by	 exit	 prior	 to	 anaphase	 (43%).	
Contrastingly	cytokinesis	failure	only	contributed	to	19%	of	all	progeny	becoming	bi-
nucleated.	 The	 epithelial	 cells	 overexpressing	 Plk1	 also	 had	 a	 much	 higher	
percentage	of	abnormal	mitosis	whereas	all	control	cells	underwent	normal	division.	
Mitosis	 in	 the	 control	 cells	 lasted	 an	 average	 of	 58min	 whereas	 the	 cells	
overexpressing	Plk1	only	managed	 to	exit	mitosis	 at	 an	average	of	 101min	 (Figure	
3.21a-d).	 This	 suggested	 mammary	 epithelial	 cells	 were	 more	 susceptible	 to	 the	
effects	induced	by	Plk1	overexpression,	thus	providing	a	suitable	explanation	to	the	
phenotypes	observed	in	vivo.		
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Figure	3.22:	 Immunofluorescence	against	pericentrin	 in	mammary	3D	cultures	and	quantification	of	
percentage	of	cells	per	organoid	with	1,2	or	3	centrosomes	at	48h	on	doxycycline	(Ctrl:	n=204;	Plk1:	
n=312)	***p	<	0.001;	Mann-Whitney	Test.	Number	of	animals:	(CTRL:	3;	Plk1:	3);	Scale	bar	20μm.  
	
As	 was	 the	 case	 with	 the	 MEFs	 (Figure	 3.19)	 and	 in	 vivo	 in	 the	 mammary	 gland	
(Figure	 3.9b),	 tetraploidization	 due	 to	 Plk1	 overexpression	 resulted	 in	 cells	 with	
supernumerary	 centrosomes	 as	 evidenced	 by	 immunofluorescence	 against	
pericentrin	in	mammary	3D	cultures.	Post	induction	of	Plk1	expression,	there	was	a	
significant	 increase	 in	 the	 percentage	 of	 cells	 per	 organoid	 with	 3	 or	 more	
centrosomes	 when	 compared	 to	 controls	 (Figure	 3.22).	 These	 findings	 are	 in	 line	
with	the	in	vivo	and	in	vitro	data	presented	earlier.	
Summary	of	Results	
The	following	were	the	main	findings	from	this	section:	
Ø Overexpression	of	Plk1	does	not	lead	to	oncogenic	transformation	in	vivo.	
Ø Increased	 Plk1	 levels	 lead	 to	 tumor	 suppression	 in	 Her2	 and	 Kras	 driven	
murine	breast	cancer	models.	
Ø Tumors	 with	 elevated	 Plk1	 show	 evidence	 of	 genome	 doubling	 and	 have	
increased	levels	of	aneuploidy	but	they	display	a	proliferative	disadvantage.	
Ø PLlk1	overexpression	impairs	chromosome	segregation	leading	to	tetraploidy	
and	reduced	proliferation	in	vitro.	
Ø Tetraploidization	results	in	mitotic	aberrations	and	centrosome	defects.	
Ø Reduction	of	Sgo1,	during	prometaphase	 is	 responsible	 for	 loss	of	 cohesion	
and	possibly	the	lack	of	chromosome	segregation.	
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Discussion	
Plk1	has	been	 the	 subject	of	 great	 interest	over	 the	 last	 few	decades.	 Since	 it	 is	 a	
prominent	 kinase	with	 several	 well-characterized	 functions	 in	 cell	 cycle	 regulation	
and	the	fact	that	it	is	overexpressed	in	many	solid	tumors	made	it	a	prime	target	for	
therapy	(Eckerdt,	Yuan	and	Strebhardt,	2005).	However,	following	limited	success	in	
clinical	trials	using	specific	small	molecule	inhibitors,	interest	has	waned	on	pursuing	
Plk1	 as	 a	 potential	 target	 for	 therapy	 and	 it	 has	 been	 slowly	 relegated	 to	 the	
sidelines.	Although	vested	 interests	have	moved	on	 to	more	promising	 treatments	
for	the	ever-evolving	disease	that	is	cancer,	in	this	study	we	revisit	Plk1	pondering	if	
is	 worth	 considering	 as	 a	 therapeutic	 target	 and	 explore	 in	 detail	 the	 molecular	
mechanisms	associated	with	Plk1	overexpression	in	mouse	models	of	breast	cancer.	
This	work	also	elucidates	the	importance	of	such	pre-clinical	studies	and	usage	of	in	
vivo	mouse	models	as	a	tool	for	validation,	prior	to	further	investment	in	large-scale	
clinical	trials.		
4.1	Tumor	suppressive	role	of	Plk1	
Plk1	 overexpression	 as	 part	 of	 the	 CIN70	 signature	 is	 usually	 associated	with	 bad	
prognosis	and	aggressive	 tumor	phenotypes	 in	human	cancer	 (Carter	et	al.,	 2006).	
Although	Plk1	is	overexpressed	in	several	different	tumors,	its	role	in	tumor	initiation	
and	 development	 is	 yet	 to	 be	 determined	 (Cholewa,	 Liu	 and	 Ahmad,	 2013).	 To	
address	this	question	my	collaborators	from	the	Malumbres	laboratory	at	the	CNIO	
developed	 a	 tetracycline-inducible	 mouse	 model	 for	 studying	 the	 effects	 of	 Plk1	
overexpression.	
This	mouse	model	uses	a	Tet-ON	system	where	Plk1	expression	is	under	the	control	
of	the	Rosa26	ubiquitous	promoter.	When	gene	expression	was	induced	throughout	
the	animal	with	the	addition	of	doxycycline,	there	was	no	significant	increase	in	the	
incidence	 of	 tumors	 when	 compared	 to	 control	 animals	 (Section	 3.1).	 Plk1	
overexpression	 did	 not	 display	 any	 significant	 oncogenic	 potential	 in	 this	 mouse	
model.	These	results	were	largely	surprising	because	experimental	overexpression	of	
other	 genes	 from	 the	 CIN70	 signature	 led	 to	 spontaneous	 tumor	 development	 in	
those	GEMMs	(Sotillo	et	al.,	2007;	Nam	and	Van	Deursen,	2014).		
Albeit	the	fact	that	Plk1	overexpression	on	its	own	was	not	sufficient	to	significantly	
increase	neoplastic	transformation,	we	postulated	that	it	could	cooperate	with	other	
oncogenic	drivers	and	accelerate	tumor	onset.	For	the	verification	of	this	hypothesis,	
we	established	mouse	models	to	study	the	effect	of	elevated	levels of	Plk1	in	Kras	or	
Her2	driven	mammary	 tumorigenesis.	 In	 line	with	previous	work	 from	our	 lab	and	
current	 literature,	 when	 mutant	 Kras	 (KrasG12D)	 or	 Her2	 is	 overexpressed	 mice	
develop	palpable	mammary	gland	tumors	with	complete	penetrance	and	an	average	
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latency	 of	 155	 and	 98	 days	 respectively.	 However,	when	 Plk1	 overexpression	was	
combined	with	 these	 potent	 oncogenes	 the	 ultimate	 result	 was	 an	 overwhelming	
tumor	 suppressive	 effect	 accompanied	 by	 a	 severe	 delay	 in	 tumor	 onset	 (Section	
3.2).		
These	findings	were	in	direct	contradiction	with	the	current	consensus	in	the	field	as	
well	 as	 our	 initial	 hypothesis.	 Although	 the	 results	 obtained	 here	 do	 reinforce	 the	
major	 findings	 from	a	 prior	 study	 conducted	 in	 our	 lab.	 This	 study	 clearly	 showed	
that	overexpression	of	Mad2	also	delayed	mammary	tumorigenesis	in	Kras	and	Her2	
breast	cancer	models,	as	a	consequence	of	prolonged	mitotic	arrest	and	 increased	
apoptosis	 (Rowald	 et	 al.,	 2016).	 Mad2	 is	 also	 a	 member	 of	 the	 CIN70	 signature,	
allowing	us	to	hypothesize	that	overexpression	of	genes	belonging	to	CIN70	can	lead	
to	tumor	suppressive	effects	in	a	tissue	specific	context.	Although	several	of	the	CIN	
genes	have	been	shown	to	be	tumor	promotive,	why	is	it	in	this	case	we	observe	the	
opposite	 effect?	 A	 major	 reasoning	 behind	 this	 is	 the	 tissue	 specific	
microenvironment	which	 plays	 a	 pivotal	 role	 in	 tumorigenesis	 (Polyak	 and	 Kalluri,	
2010).	 Another	 possible	 explanation	would	 be	 the	 higher	 cell	 turnover	 rate	 in	 the	
breast	 compared	 to	 other	 tissues,	 owing	 to	 hormonal	 fluctuations	 caused	 by	 the	
estrus	cycle	(Visvader	and	Stingl,	2014).		
The	final	result	might	be	similar	in	both	cases	but	the	path	taken	to	reach	it	could	be	
vastly	different,	in	other	words,	the	mechanism	by	which	Plk1	overexpression	leads	
to	 tumor	 suppression	 can	 vary	 significantly	 from	 Mad2.	 Considering	 the	 distinct	
functions	of	both	proteins	 this	would	be	the	 likely	scenario;	 it	 is	 thus	 important	 to	
determine	 the	 exact	 reasoning	 behind	 the	 tumor	 deterring	 phenotype	 caused	 by	
elevated	levels	of	Plk1. 
4.2	Genome	Doubling	in	Tumors,	a	Consequence	of	Plk1	Overexpression?	
In	 the	 introduction	 section,	 it	was	mentioned	how	whole	genome	doubling	events	
are	 a	 relatively	 common	 occurrence	 during	 tumor	 development	 with	 a	 significant	
portion	of	 these	 tumors	 still	maintaining	a	near	 tetraploid	 karyotype	 (Dewhurst	et	
al.,	2014).	Hence,	 it	 is	not	surprising	to	observe	tetraploid	or	polyploid	cells	also	 in	
mouse	 tumor	 models,	 which	 recapitulate	 human	 disease.	 Histological	 analysis	 of	
tumors	 from	 our	 mouse	 models	 however	 revealed	 a	 significant	 increase	 in	 the	
percentage	of	polyploid	cells	specifically	in	tumors	overexpressing	Plk1	compared	to	
single	oncogene	tumors.	These	observations	eluded	at	a	probable	role	of	the	protein	
in	inducing	genome	doubling	(Section	3.3).	A	strong	possibility	considering	the	many	
roles	 the	 kinase	 plays	 during	 cell	 division	 and	 that	 tetraploidization	mainly	 results	
from	a	failure	in	the	cell	division	machinery	(Davoli,	de	Lange	and	Lange,	2011).	
A	 comprehensive	 analysis	 performed	 by	 our	 collaborator,	 Nicholas	 McGranahan	
(UCL),	 utilizing	 the	 TCGA	 BRCA	 dataset	 (cancergenome.nih.gov),	 consisting	 of	 954	
	45	
	
patient	 samples	 of	 breast	 invasive	 carcinoma	 revealed	 a	 significant	 correlation	
between	 Plk1	 expression	 and	 genome	 doubling	 in	 these	 tumors	 (Figure	 4.1).	 The	
results	of	this	analysis	firmly	corroborate	the	observations	made	in	our	mouse	tumor	
models.	The	distinct	possibility	that	elevated	levels	of	Plk1	causes	genome	doubling	
also	 in	 human	 tumors	 lends	 credibility	 to	 this	 study	 as	 well	 as	 emphasizes	 the	
importance	of	these	GEMMs	for	further	use	in	preclinical	testing.	
	
Figure	 4.1:	 Plk1	 expression	 relative	 to	 TATA	 box	 protein	 (TBP)	 in	 genome	 doubled	 (GD)	 and	 non-
genome	doubled	(nGD)	tumors	of	the	TCGA	BRCA	dataset	(n=954	breast	 invasive	carcinoma	patient	
samples).	 Analysis	 performed	 by	 Nicholas	 McGranahan	 (UCL)	 at	 the	 behest	 of	 personal	
correspondence	(unpublished	data).	
Recent	 studies	 have	 shown	 that	 whole	 genome	 doubling	 promotes	 genomic	
instability,	driving	evolution	and	resulting	in	tumors	with	complex	karyotypes.	This	is	
attributed	to	the	fact	that	the	whole	genome	doubling	results	 in	extra	copies	of	all	
chromosomes	 and	 although	 these	 tetraploids	 are	 generally	 stable,	 their	 larger	
genomic	 pool	 allows	 them	 a	 higher	 tolerance	 towards	 chromosome	 gain	 or	 loss	
compared	 to	diploid	cells	 (Dewhurst	et	al.,	2014).	The	 results	obtained	here	are	 in	
concurrence	with	these	findings.	The	tumors	with	elevated	Plk1	levels	indeed	show	a	
higher	 percentage	 of	 aneuploidy,	 which	 is	 a	 direct	 consequence	 of	 the	 genomic	
instability	(Figure	3.4).	It	is	also	known	that	tumors	with	high	levels	of	aneuploidy	are	
more	 resilient	 to	 targeted	 therapy	 and	 can	 also	 be	 the	 cause	 of	 the	 increase	 in	
relapses	post-treatment.	The	probability	is	high	that	this	is	also	the	case	with	these	
murine	tumors	overexpressing	Plk1,	although	this	could	not	be	confirmed	during	this	
current	 project.	 We	 can,	 however,	 derive	 a	 conclusion	 because	 human	 tumors	
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overexpressing	Plk1	generally	show	a	poorer	prognosis	following	primary	treatment	
(kmplot.com).	
The	 frequent	 occurrence	 of	 genome	 doubled	 cells	 in	 these	 tumors	 still	 does	 not	
provide	 an	 explanation	 for	 the	 tumor	 suppression	 caused	 by	 Plk1.	 Studies	 have	
shown	 that	 tetraploid	 cells,	 in	 general,	 have	 a	 reduced	 proliferative	 potential	
compared	to	their	diploid	counterparts	and	can	be	denoted	as	less	fit.	This	reduced	
proliferation	 is	 attributed	 to	 a	 p53	 dependent	 cell	 cycle	 (G1)	 arrest	 eventually	
leading	to	cell	senescence	or	apoptosis.	There	is	no	specific	tetraploid	checkpoint	in	
existence,	meaning	cells	have	no	method	of	verifying	correct	chromosome	number	
(Reviewed	 by	 Ganem	 and	 Pellman,	 2007).	 However,	 following	 failed	 cell	 division	
several	 triggers,	 which	 cause	 cell	 cycle	 arrest	 and	 apoptosis,	 can	 activate	 p53,	
leading	 to	 the	 activation	 of	 the	 Hippo	 tumor	 suppressor	 pathway.	 The	 Hippo	
pathway	is	induced	partially	due	to	the	presence	of	extra	centrosomes	in	tetraploid	
cells	 which	 activates	 the	 kinase	 LATS2,	 causing	 stabilization	 of	 p53	 and	 finally	
resulting	in	the	inhibition	of	YAP	and	TAZ	(Ganem	et	al.,	2014).		
 
Figure	4.2:	Triggers	that	lead	the	activation	of	p53	following	failed	cell	division	and	the	consequences	
(Ganem	and	Pellman,	2007).	
The	direct	effector	of	p53	activation	following	these	events	is	p21,	which	causes	cell	
cycle	arrest	at	the	G1	phase.	We	questioned	if	this	was	observed	also	in	the	case	of	
tumors	 overexpressing	 Plk1,	 which	 displayed	 a	 high	 percentage	 of	 polyploid	 cells.	
Immunohistochemistry	 analysis	 of	 p21	 expression	 in	 Plk1	 tumors	 showed	 a	
	47	
	
significantly	 higher	 percentage	 of	 p21	 positive	 cells	 in	 comparison	 to	 the	 single	
oncogene	 counterparts	 (Figure	 3.5a).	 Moreover,	 tumors	 with	 elevated	 Plk1	 also	
displayed	 a	 reduced	 proliferative	 potential	 as	 evidenced	 by	 PCNA	 staining.	 PCNA,	
which	 is	 a	marker	 of	 cellular	 proliferation,	 was	 found	 to	 be	 expressed	 in	 a	 lesser	
percentage	of	cells	in	the	Plk1	tumors	compared	to	the	Kras	or	Her2	tumors	(Figure	
3.5b).	 Considered	 together	 we	 conclude	 that	 tumors	 overexpressing	 Plk1	 have	
increased	 karyotype	 complexity,	 elevated	 percentage	 of	 polyploid	 cells	 but	 also	
displays	a	decrease	in	proliferation	due	to	p21	induced	cell	cycle	arrest.	
4.3	Effect	of	Plk1	prior	to	Tumor	Initiation	
Previously,	we	discussed	the	tumor	suppressive	role	of	Plk1	as	well	as	the	potential	
effects	of	Plk1	overexpression	on	the	tumors	themselves.	However,	it	must	be	noted	
that	 the	 major	 phenotype	 observed	 in	 these	 cancer	 models	 is	 an	 overwhelming	
suppression	of	oncogenic	transformation,	with	90%	of	the	Kras/Plk1	and	56%	of	the	
Her2/Plk1	animals	not	developing	tumors	(Section	3.1).	Therefore,	it	was	mandatory	
to	study	the	effects	of	Plk1	overexpression	on	the	mammary	glands	prior	to	tumor	
initiation.	
We	investigated	two	separate	time	points	to	further	explore	the	role	of	Plk1	in	early	
stages	prior	to	tumor	development.	Mammary	glands	harvested	4	and	100	days	post	
transgene	induction	showed	a	stable	expression	of	Plk1	in	all	mouse	models	across	
both	 time	 points	 (Figure	 3.6).	 Fold	 change	 of	 the	 Plk1	 transgene	 as	measured	 by	
qPCR	 was	 comparable	 to	 what	 was	 observed	 in	 human	 breast	 cancer	 cell	 lines,	
validating	the	efficacy	of	this	model	system	in	mimicking	the	human	scenario	(Figure	
3.7).		
The	results	obtained	here	indicated	that	Plk1	overexpression	has	a	noticeable	effect	
on	the	cellular	morphology	in	the	mammary	gland	as	early	as	4	days	after	induction.	
While	the	structure	of	the	mammary	acini	itself	remains	unaffected,	Plk1	caused	an	
increase	 in	 the	 number	 of	 cells	 with	 a	 larger	 nuclear	 volume	 which	 is	 a	 clear	
indication	 of	 polyploidy	 (Figure	 3.8).	 A	 recent	 study	 on	 mammary	 glands	 during	
lactation	 revealed	 the	 presence	 of	 naturally	 occurring	 polyploid	 cells	 arising	 from	
failed	cytokinesis.	The	generation	of	these	cells	was	dependent	on	overexpression	of	
Aurora	 kinase-A	 as	well	 as	 Plk1	 and	 it	was	 also	 suggested	 that	 this	 is	 a	 conserved	
mechanism	 essential	 for	 the	 lactation	 process.	 This	 was	 followed	 by	 the	 rapid	
clearance	 of	 these	 polyploid	 cells	 by	 apoptosis	 which	 occurred	 post	 pregnancy	 to	
prevent	possible	malignant	transformation	(Rios	et	al.,	2016).			
Therefore,	the	mammary	gland	is	an	organ	that	inherently	shows	a	higher	tolerance	
towards	 polyploidy	 induced	 by	 Plk1	 overexpression	 and	 has	 an	 intrinsic	 apoptotic	
mechanism	that	clears	these	cells,	which	is	nonexistent	in	other	tissues.	This	is	one	
of	 the	strong	possibilities	of	how	the	 transformation	of	polyploid	cells	 is	 limited	 in	
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breast	 tissue.	 The	 other	 explanation	 is	 that	 irrespective	 of	 a	 tissue	 specific	
mechanism,	 just	 the	 presence	 of	 polyploid	 cells	 themselves	 can	 lead	 to	 cell	 cycle	
arrest,	apoptosis	and	activation	of	tumor	suppressor	pathways,	as	discussed	earlier.	
Despite	 polyploid	 cells	 being	 less	 fit	 they	 have	 an	 inherently	 higher	 potential	 for	
oncogenic	 transformation	 and	 by	 removing	 these	 cells	 from	 active	 cycling	 this	
effectively	reduces	the	probability	of	transformation	occurring	in	the	tissue.	In	either	
case,	 the	presence	of	 polyploidy	 at	 an	 early	 stage	provides	 an	 explanation	 for	 the	
strong	 tumor	 suppressive	 effect	 observed	 in	 the	 Plk1	 expressing	 cohorts.	 This	 is	
further	supported	by	the	increase	in	apoptosis	seen	in	the	mammary	gland	cells	over	
expressing	Plk1	(Figure	3.9b).		
4.4	Mechanisms	inducing	Polyploidy	and	their	consequences	
It	was	clear	that	the	antiproliferative	and	tumor	suppressive	effects	of	Plk1	were	a	
direct	result	of	the	induced	polyploidy.	With	Plk1	partaking	in	different	phases	of	the	
cell	 cycle	 (Petronczki,	 Lenart	 and	 Peters,	 2008),	 it	 proved	 to	 be	 a	 challenge	 to	
pinpoint	 the	 exact	 function	 of	 the	 kinase	 that	 was	 responsible	 for	 the	 observed	
phenotype.	 It	 has	 long	 been	 known	 that	 Plk1	 overexpression	 leads	 to	
tetraploidization,	 however,	 the	 mechanism	 causing	 it	 has	 not	 been	 concretely	
established	(Meraldi,	Honda	and	Nigg,	2002).		
Time-lapse	imaging	of	H2B-GFP	labeled	MEFs	overexpressing	Plk1	provided	hints	for	
unraveling	 this	 mechanism.	 In	 line	 with	 our	 in	 vivo	 results,	 the	 findings	 here	
indicated	 that	 over	 60%	 of	 cells	 entering	 mitosis	 failed	 to	 complete	 cell	 division	
resulting	in	a	genome	doubled	tetraploid	progeny.	Based	on	these	observations,	cell	
fate	can	be	determined	by	one	of	these	three	possibilities.	Either	there	was	a	failure	
in	segregation	due	to	impaired	chromosome	alignment	followed	by	mitotic	exit	prior	
to	 anaphase	 resulting	 in	 a	 fused	 nucleus	 (27%)	 or	 cytokinesis	 failure	 occurred	
forming	a	bi-nucleated	cell	 (38%).	There	were	also	a	small	percentage	(7%)	of	cells	
that	underwent	mitotic	regression	after	anaphase	(Figure	3.11).		
While	 we	 explored	 the	 broader	 implications	 of	 genome	 doubling	 and	 the	 roles	 it	
could	 play	 in	 tumorigenesis,	 what	 would	 be	 the	 immediate	 effects	 of	
tetraploidization	at	a	cellular	 level?	Plk1	overexpressing	cells	showed	a	high	rate	of	
erroneous	 division	 with	 most	 of	 the	 cells	 becoming	 tetraploid,	 one	 of	 the	 main	
consequences	 is	 these	cells	ending	up	with	extra	centrosomes	as	shown	 in	section	
3.14.	 Supernumerary	 centrosomes	 are	 a	 norm	 in	 tetraploid	 cells	 that	 result	 from	
failed	 cell	 division	 (Meraldi,	 Honda	 and	 Nigg,	 2002)	 and	 the	 presence	 of	 extra	
centrosomes	 can	 lead	 to	 further	 mitotic	 aberrations	 such	 as	 multipolar	 spindles,	
lagging	 chromosomes	 and	 bridges	 as	 seen	 in	 Figure	 3.9a.	 The	 schematic	 below	
(Figure	4.3)	proposes	a	mechanism	that	explains	how	tetraploid	cells	with	aberrant	
centrosomes	that	can	bypass	the	p53	checkpoint	result	in	aneuploid	progeny	during	
the	following	rounds	of	cell	divisions.	This	model	also	lends	more	credibility	to	what	
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was	 discussed	 earlier.	 However,	 a	 recent	 study	 has	 shown	 that	 centrosome	
amplification	caused	directly	by	overexpression	of	Plk4	can	act	as	a	driving	force	for	
oncogenic	transformation	even	with	functional	copies	of	p53	present	(Levine	et	al.,	
2017).	 Counter	 to	 this	 is	 the	 findings	 by	 Ganem	 et	 al.	 (2014)	which	 revealed	 that	
extra	 centrosomes	 resulting	 from	 tetraploidization	 can	 indirectly	 cause	 p53	
stabilization	 and	 the	 activation	 of	 tumor	 suppressive	 pathway.	 Possessing	 extra	
centrosomes	 can	 thus	 lead	 to	 both	 tumor	 promoting	 and	 suppressive	 effects	
depending	 on	 the	 situation. In	 the	 models	 described	 in	 this	 thesis,	 Plk1	
overexpression	in	the	mammary	gland	resulted	in	a	tumor	suppressive	effect.	In	the	
future, it	would	be	interesting	to	test	whether	overexpression	of	Plk1	together	with	
other	oncogenic	drivers	or	even	 in	combination	with	 the	absence	of	certain	 tumor	
suppressor	genes	will	have	the	same	effect. Finally,	whether	elevated	levels	of	Plk1	
in	other	tissues	will	result	in	similar	outcomes	is	also	worth	exploring.		
 
Figure	 4.3:	 Impaired	 cell	 division	 results	 in	 tetraploid	 cells	 with	 supernumerary	 centrosomes.	 The	
proposed	 model	 indicates	 that	 upon	 failed	 mitotic	 exit	 cells	 carry	 an	 extra	 centrosome,	 these	
tetraploid	cells	are	eliminated	 in	a	p53	wildtype	background.	The	cells	 that	evade	 this	or	possess	a	
p53	mutation	go	through	S	phase	producing	a	polyploid	cell	with	4	centrosomes,	these	cells	are	prone	
to	aneuploidy	(Meraldi,	Honda	and	Nigg,	2002).	
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All	evidence	points	out	that	the	method	of	acquiring	extra	centrosomes	in	the	MEFs	
is	 indeed	 failed	 mitosis.	 It	 could,	 however,	 be	 argued	 that	 the	 phenotype	 of	
supernumerary	 centrosomes	 could	be	directly	 caused	by	Plk1	overexpression.	 This	
argument	 is	 plausible	 because	 Plk1	 is	 essential	 for	 centrosome	 maturation	 and	
separation	(Nam	and	Van	Deursen,	2014;	Wang	et	al.,	2014),	the	overexpression	of	
the	 kinase	 could	 affect	 these	 functions	 thereby	 indirectly	 affecting	 centrosome	
number.	Our	study	found	no	evidence	in	support	of	this,	elevated	levels	of	activated	
pPlk1	at	the	centrosomes	was	only	observed	at	the	late	G2	phase	(Figure	3.17)	after	
duplication	and	 separation	have	already	occurred,	 concluding	 that	 increase	 in	Plk1	
did	not	interfere	with	centrosome	duplication.	
4.5	Tetraploidization	by	Impaired	Chromosome	Segregation	or	Cytokinesis	Failure		
Even	though	cytokinesis	failure	was	one	of	the	major	routes	leading	to	tetraploidy	in	
the	MEFs,	in	this	study	we	decided	to	emphasize	on	chromosome	segregation	failure	
and	premature	mitotic	exit	as	 the	main	mechanism	driving	polyploidy.	There	are	a	
few	reasons	to	justify	this	decision,	first,	there	was	a	higher	frequency	of	the	lack	of	
segregation	phenotype	compared	to	cytokinesis	failure	occurring	when	mitosis	was	
monitored	 in	 mammary	 organoid	 cultures	 overexpressing	 Plk1	 (Figure	 3.18),	 the	
organoids	are	the	more	relevant	system	for	this	study.	Second,	there	was	a	 lack	of	
evidence	of	bi-nucleation	 in	 vivo	 in	 the	mouse	breast	 tissue	after	 induction	of	 the	
transgene	(data	not	shown).	However,	 it	can	also	be	argued	that	bi-nucleated	cells	
are	 an	 intermediate	existence	which	will	 eventually	 result	 in	polyploid	 cells	 during	
subsequent	rounds	of	cell	division	(Meraldi,	Honda	and	Nigg,	2002).	The	final	reason	
is	 simply	 that	 lack	 of	 segregation	 and	 the	 premature	 mitotic	 exit	 happen	 before	
anaphase	 whereas	 cytokinesis	 failure	 can	 only	 occur	 during	 the	 final	 phase	 of	
mitosis,	hence	it	can	be	reasoned	that	only	the	cells	that	escape	the	first	phenotype	
can	undergo	cytokinesis	failure	making	it	a	secondary	effect.	
To	 understand	 the	 causative	 factors	 that	 led	 to	 the	 failure	 of	 chromosome	
segregation,	 we	 first	 checked	 the	 localization	 and	 activation	 of	 Plk1	 at	 different	
phases	 of	 mitosis.	 Plk1	 activity	 was	 found	 to	 be	 increased	 in	 prometaphase	 and	
metaphase,	 24	 hours	 post	 induction	 (Figure	 3.12),	 there	 was	 also	more	 activated	
Plk1	 localized	 specifically	 at	 the	 centromeric	 region	 during	 prometaphase	 (Figure	
3.13a).	One	of	the	major	functions	of	Plk1	that	could	be	the	cause	of	the	observed	
phenotype	is	the	role	of	the	kinase	in	disrupting	cohesion.	Under	normal	conditions	
Plk1	 is	 responsible	 for	the	phosphorylation	of	Sgo1	and	removing	the	protein	from	
its	centromeric	localization	at	anaphase,	this	allows	separase	to	cleave	cohesion	and	
sister	 chromatids	 are	 pulled	 apart.	 The	 phosphatase	 PP2A	which	 is	 an	 inhibitor	 of	
Plk1	 function	 prevents	 this	 from	 happening	 prematurely	 (Kitajima	 et	 al.,	 2006).	
However,	 with	 the	 overexpression	 of	 Plk1	 in	 this	 model	 and	 the	 increase	 in	
accumulation	 of	 activated	 Plk1	 at	 prometaphase,	 the	 loss	 of	 Sgo1	 from	 the	
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centromeres	 can	 happen	 earlier	 thereby	 affecting	 cohesion.	 The	 results	 obtained	
also	 were	 in	 support,	 partial	 or	 complete	 cohesion	 loss	 was	 more	 frequently	
observed	 in	 chromosome	 spreads	 of	MEFs	with	 Plk1	 overexpression	 (Figure	 3.14).	
The	 decrease	 in	 Sgo1	 expression,	 as	 well	 as	 diffused	 Sgo1	 localization,	 was	 also	
observed	 in	 these	 cells,	 further	 reinforcing	 this	 hypothesis	 (Figure	 3.15a).	 Loss	 of	
Sgo1	 has	 been	 shown	 to	 cause	 mitotic	 arrest	 and	 premature	 mitotic	 exit	
(McGuinness	et	al.,	2005),	these	findings	are	in	line	with	our	findings	which	showed	
an	increase	in	mitotic	duration	and	exit	without	segregation	(Figure	3.11a,	d).	
Figure	4.4:	Plk1	mediates	centromeric	cohesion.	In	
this	 model,	 Plk1	 phosphorylates	 Sgo1	 effectively	
removing	 it	 from	 the	 centromeres	 and	 exposes	
cohesion	 for	 degradation.	 PP2A	 counteracts	 this	
function	of	Plk1	(Shintomi	and	Hirano,	2010).	
	
Even	 though	 we	 did	 not	 observe	 a	 significant	 increase	 in	 activated	 pPlk1	 at	 the	
midbody	during	cytokinesis,	this	still	warranted	further	study	since	bi-nucleation	by	
cytokinesis	failure	was	a	prominent	occurrence	in	Plk1	overexpressing	MEFs	and	was	
also	 observed	 to	 a	 lesser	 degree	 in	mammary	 3D	 cultures.	 Experiments	 that	were	
conducted	 to	 explore	 this	 phenotype	 are	 not	 a	 part	 of	 this	 dissertation,	 however,	
work	carried	out	by	our	collaborators	at	the	Malumbres	 laboratory	offer	a	suitable	
explanation	 for	 this	 phenomenon.	 The	 results	 of	 that	 study	 confirmed	 the	
occurrence	of	 aberrant	 cytokinesis	 in	MEFs	 and	 concluded	 that	over	 expression	of	
Plk1	hindered	the	 localization	of	 the	components	belonging	to	the	ESCRT	complex,	
which	 was	 essential	 for	 abscission.	 One	 of	 the	 key	 components	 required	 for	 the	
assembly	of	this	complex	is	Cep55,	which	is	a	target	of	Plk1.	The	phosphorylation	of	
Cep55	by	 Plk1	 prevents	 its	 localization	 to	 the	midbody	until	 the	 end	of	 anaphase,	
when	the	levels	of	Plk1	drop	at	the	end	of	anaphase	Cep55	can	properly	localize	and	
abscission	can	take	place	(Figure	4.5).	When	Plk1	is	overexpressed	the	localization	of	
Cep55	and	TSG101,	which	is	another	component	of	the	complex	were	both	hindered	
and	cytokinesis	failure	occurred	due	to	a	lack	of	abscission	(unpublished	data).		
A	combination	of	both	mechanisms	increased	the	accumulation	of	polyploid	cells	in	
Plk1	overexpressing	 in	 vitro	 culture	 systems.	We	 can	also	extend	 these	 findings	 to	
provide	a	justification	for	the	increase	in	polyploidy	observed	in	the	mouse	models.	
	
	
	
	52	
	
Figure	 4.5:	 Assembly	 of	 ESCRT	 complex	 and	 the	
end	of	 cytokinesis.	 Plk1	blocks	 the	 localization	of	
Cep55	that	 is	essential	 for	 the	recruitment	of	 the	
other	 components	 of	 the	 abscission	 complex.	
Figure	adapted	from	(Carmena,	2012).	
	
	
	
	
4.6	Concluding	Remarks	
During	 this	 project,	 we	 investigated	 the	 potential	 role	 of	 Plk1	 to	 function	 as	 an	
oncogene	in	vivo	and	further	explored	if	elevated	levels	of	Plk1	could	have	any	effect	
on	tumor	initiation	in	the	presence	of	other	more	prominent	oncogenic	drivers.	The	
results	 were	 quite	 contradictory	 to	 current	 consensus,	 Plk1	 not	 only	 failed	 to	
function	as	an	oncogene,	 in	addition,	 it	proved	to	be	a	potent	tumor	suppressor	of	
Her2	and	Kras	driven	breast	cancer.	
Further	 study	 using	 in	 vitro	 systems	 to	 explore	 the	 mechanism	 revealed	 that	
overexpression	of	Plk1	 led	to	 faulty	chromosome	segregation,	with	over	60%	of	all	
mitotic	 divisions	 resulting	 in	 tetraploid	 progeny,	 this	 also	 resulted	 in	 centrosomes	
defects	among	 the	said	progeny	with	most	of	 them	possessing	extra	centrosomes.	
This	 phenotype	 was	 also	 well	 reflected	 in	 vivo	 in	 the	 mammary	 gland	 as	 well	 as	
observed	 in	 the	 tumors	 with	 high	 Plk1	 expression.	 Though	 recent	 studies	 have	
shown	 that	 polyploidy,	 as	well	 as	 centrosome	 amplification	 can	 have	 a	 prominent	
effect	on	promoting	tumorigenesis,	we	have	explored	how	the	early	stage	induction	
of	this	phenotype	can	lead	to	a	strong	tumor	suppressive	effect	in	this	context.	Even	
though	Plk1	lead	to	tumor	suppression	in	most	of	the	colony,	the	small	percentage	
of	 tumors	 with	 elevated	 Plk1	 levels	 displayed	 a	 complex	 karyotype	 thus	 further	
validating	existing	studies	that	state	polyploidy	allows	for	the	tolerance	of	more	CIN.	
It	must	be	stated	that	 the	conclusions	drawn	from	this	work	are	not	necessarily	 in	
contradiction	 of	 using	 Plk1	 inhibitors	 for	 targeted	 therapy.	 Although	 Plk1	
overexpression	in	this	context	acted	as	a	tumor	suppressor,	when	induced	at	a	later	
stage	of	tumor	development	it	could	have	the	opposite	effect,	possibly	after	the	loss	
of	the	tumor	suppressor	p53.	Even	if	this	were	not	to	be	the	case,	the	inhibition	of	
Plk1	 in	 human	 tumors	 could	 still	 have	 an	 anti-tumor	 effect	 simply	 due	 to	 the	
importance	of	the	kinase	during	cell	division.	This	study	is	directed	to	elucidate	the	
molecular	mechanisms	associated	with	Plk1	overexpression	and	speculates	how	this	
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knowledge	could	be	beneficial	for	gaining	a	better	understanding	for	the	proper	use	
of	Plk1	specific	inhibitors	during	treatment.		
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